1
|
Fransson C, Barlow MJ, Kavanagh PJ, Larsson J, Jones OC, Sargent B, Meixner M, Bouchet P, Temim T, Wright GS, Blommaert JADL, Habel N, Hirschauer AS, Hjorth J, Lenkić L, Tikkanen T, Wesson R, Coulais A, Fox OD, Gastaud R, Glasse A, Jaspers J, Krause O, Lau RM, Nayak O, Rest A, Colina L, van Dishoeck EF, Güdel M, Henning T, Lagage PO, Östlin G, Ray TP, Vandenbussche B. Emission lines due to ionizing radiation from a compact object in the remnant of Supernova 1987A. Science 2024; 383:898-903. [PMID: 38386759 DOI: 10.1126/science.adj5796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 01/12/2024] [Indexed: 02/24/2024]
Abstract
The nearby Supernova 1987A was accompanied by a burst of neutrino emission, which indicates that a compact object (a neutron star or black hole) was formed in the explosion. There has been no direct observation of this compact object. In this work, we observe the supernova remnant with JWST spectroscopy, finding narrow infrared emission lines of argon and sulfur. The line emission is spatially unresolved and blueshifted in velocity relative to the supernova rest frame. We interpret the lines as gas illuminated by a source of ionizing photons located close to the center of the expanding ejecta. Photoionization models show that the line ratios are consistent with ionization by a cooling neutron star or a pulsar wind nebula. The velocity shift could be evidence for a neutron star natal kick.
Collapse
Affiliation(s)
- C Fransson
- Department of Astronomy, Stockholm University, The Oskar Klein Centre, AlbaNova, SE-106 91 Stockholm, Sweden
| | - M J Barlow
- Department of Physics and Astronomy, University College London, London WC1E 6BT, UK
| | - P J Kavanagh
- Department of Experimental Physics, Maynooth University, Maynooth, County Kildare, Ireland
- Astronomy & Astrophyics Section, School of Cosmic Physics, Dublin Institute for Advanced Studies, Dublin 2, Ireland
| | - J Larsson
- Department of Physics, KTH Royal Institute of Technology, The Oskar Klein Centre, AlbaNova, SE-106 91 Stockholm, Sweden
| | - O C Jones
- UK Astronomy Technology Centre, Royal Observatory, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - B Sargent
- Space Telescope Science Institute, Baltimore, MD 21218, USA
- Department of Physics and Astronomy, The Johns Hopkins University, Baltimore, MD 21218, USA
| | - M Meixner
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - P Bouchet
- Université Paris-Saclay, Université Paris Cité, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de la Recherche Scientifique, Astrophysique Instrumentation Modélisation, Saint Aubin, France
| | - T Temim
- Department of Astrophysical Sciences, Princeton University, Princeton, NJ 08544, USA
| | - G S Wright
- UK Astronomy Technology Centre, Royal Observatory, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - J A D L Blommaert
- Astronomy and Astrophysics Research Group, Department of Physics and Astrophysics, Vrije Universiteit Brussel, B-1050 Brussels, Belgium
| | - N Habel
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - A S Hirschauer
- Space Telescope Science Institute, Baltimore, MD 21218, USA
| | - J Hjorth
- Dark Cosmology Centre, Niels Bohr Institute, University of Copenhagen, 2200 Copenhagen, Denmark
| | - L Lenkić
- Stratospheric Observatory for Infrared Astronomy Science Center, Universities Space Research Association, NASA Ames Research Center, Moffett Field, CA 94035, USA
| | - T Tikkanen
- School of Physics and Astronomy, Space Research Centre, Space Park Leicester, University of Leicester, Leicester LE4 5SP, UK
| | - R Wesson
- School of Physics and Astronomy, Cardiff University, Cardiff CF24 3AA, UK
| | - A Coulais
- Université Paris-Saclay, Université Paris Cité, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de la Recherche Scientifique, Astrophysique Instrumentation Modélisation, Saint Aubin, France
- Laboratoire d'Etudes du Rayonnement et de la Matière en Astrophysique et Atmosphères, Observatoire de Paris, Paris Sciences et Lettres Research University, National Centre for Scientific Research, Sorbonne Université, Paris, France
| | - O D Fox
- Space Telescope Science Institute, Baltimore, MD 21218, USA
| | - R Gastaud
- Université Paris-Saclay, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Detectors Electronics and Computing for Physics, Gif-sur-Yvette, France
| | - A Glasse
- UK Astronomy Technology Centre, Royal Observatory, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - J Jaspers
- Department of Experimental Physics, Maynooth University, Maynooth, County Kildare, Ireland
- Astronomy & Astrophyics Section, School of Cosmic Physics, Dublin Institute for Advanced Studies, Dublin 2, Ireland
| | - O Krause
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - R M Lau
- National Optical-Infrared Astronomy Research Laboratory, National Science Foundation, Tucson, AZ 85719, USA
| | - O Nayak
- NASA Goddard Space Flight Center, Greenbelt, MD 20770, USA
| | - A Rest
- Space Telescope Science Institute, Baltimore, MD 21218, USA
- Department of Physics and Astronomy, The Johns Hopkins University, Baltimore, MD 21218, USA
| | - L Colina
- Centro de Astrobiología, Consejo Superior de Investigaciones Científicas - Instituto Nacional de Técnica Aeroespacial, Torrejón de Ardoz, E-28850, Madrid, Spain
| | - E F van Dishoeck
- Max-Planck Institut für Extraterrestrische Physik, D-85748 Garching, Germany
- Leiden Observatory, 2300 RA Leiden, Netherlands
| | - M Güdel
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
- Department of Astrophysics, University of Vienna, A-1180 Vienna, Austria
- Institute for Particle Physics and Astrophysics, Eidgenössische Technische Hochschule Zürich, 8093 Zürich, Switzerland
| | - Th Henning
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - P-O Lagage
- Université Paris-Saclay, Université Paris Cité, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de la Recherche Scientifique, Astrophysique Instrumentation Modélisation, Saint Aubin, France
| | - G Östlin
- Department of Astronomy, Stockholm University, The Oskar Klein Centre, AlbaNova, SE-106 91 Stockholm, Sweden
| | - T P Ray
- Astronomy & Astrophyics Section, School of Cosmic Physics, Dublin Institute for Advanced Studies, Dublin 2, Ireland
| | - B Vandenbussche
- Institute of Astronomy, Katholieke Universiteit Leuven, 3001 Leuven, Belgium
| |
Collapse
|
2
|
Ray TP, McCaughrean MJ, Caratti O Garatti A, Kavanagh PJ, Justtanont K, van Dishoeck EF, Reitsma M, Beuther H, Francis L, Gieser C, Klaassen P, Perotti G, Tychoniec L, van Gelder M, Colina L, Greve TR, Güdel M, Henning T, Lagage PO, Östlin G, Vandenbussche B, Waelkens C, Wright G. Author Correction: Outflows from the youngest stars are mostly molecular. Nature 2023; 623:E3. [PMID: 37845331 PMCID: PMC10620075 DOI: 10.1038/s41586-023-06744-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2023]
Affiliation(s)
- T P Ray
- Dublin Institute for Advanced Studies, Dublin, Ireland.
- School of Physics, Trinity College Dublin, Dublin, Ireland.
| | | | | | - P J Kavanagh
- Dublin Institute for Advanced Studies, Dublin, Ireland
- Department of Experimental Physics, Maynooth University, Maynooth, Ireland
| | - K Justtanont
- Department of Space, Earth and Environment, Chalmers University of Technology, Onsala Space Observatory, Onsala, Sweden
| | | | - M Reitsma
- European Space Agency, ESTEC, Noordwijk, the Netherlands
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - H Beuther
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - L Francis
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - C Gieser
- Max-Planck-Institut für Extraterrestrische Physik, Garching, Germany
| | - P Klaassen
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| | - G Perotti
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - L Tychoniec
- European Southern Observatory, Garching, Germany
| | - M van Gelder
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - L Colina
- Centro de Astrobiología (CAB, CSIC-INTA), Carretera de Ajalvir, Torrejón de Ardoz, Spain
| | - Th R Greve
- DTU Space, Technical University of Denmark, Kongens Lyngby, Denmark
| | - M Güdel
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
- Department of Astrophysics, University of Vienna, Vienna, Austria
- ETH Zürich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - Th Henning
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - P O Lagage
- Université Paris-Saclay, Université Paris Cité, CEA, CNRS, AIM, Gif-sur-Yvette, France
| | - G Östlin
- Department of Astronomy, Stockholm University, AlbaNova University Center, Stockholm, Sweden
| | | | - C Waelkens
- Institute of Astronomy, KU Leuven, Leuven, Belgium
| | - G Wright
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| |
Collapse
|
3
|
Ray TP, McCaughrean MJ, Caratti O Garatti A, Kavanagh PJ, Justtanont K, van Dishoeck EF, Reitsma M, Beuther H, Francis L, Gieser C, Klaassen P, Perotti G, Tychoniec L, van Gelder M, Colina L, Greve TR, Güdel M, Henning T, Lagage PO, Östlin G, Vandenbussche B, Waelkens C, Wright G. Outflows from the youngest stars are mostly molecular. Nature 2023; 622:48-52. [PMID: 37619607 PMCID: PMC10550818 DOI: 10.1038/s41586-023-06551-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Accepted: 08/17/2023] [Indexed: 08/26/2023]
Abstract
The formation of stars and planets is accompanied not only by the build-up of matter, namely accretion, but also by its expulsion in the form of highly supersonic jets that can stretch for several parsecs1,2. As accretion and jet activity are correlated and because young stars acquire most of their mass rapidly early on, the most powerful jets are associated with the youngest protostars3. This period, however, coincides with the time when the protostar and its surroundings are hidden behind many magnitudes of visual extinction. Millimetre interferometers can probe this stage but only for the coolest components3. No information is provided on the hottest (greater than 1,000 K) constituents of the jet, that is, the atomic, ionized and high-temperature molecular gases that are thought to make up the jet's backbone. Detecting such a spine relies on observing in the infrared that can penetrate through the shroud of dust. Here we report near-infrared observations of Herbig-Haro 211 from the James Webb Space Telescope, an outflow from an analogue of our Sun when it was, at most, a few times 104 years old. These observations reveal copious emission from hot molecules, explaining the origin of the 'green fuzzies'4-7 discovered nearly two decades ago by the Spitzer Space Telescope8. This outflow is found to be propagating slowly in comparison to its more evolved counterparts and, surprisingly, almost no trace of atomic or ionized emission is seen, suggesting its spine is almost purely molecular.
Collapse
Affiliation(s)
- T P Ray
- Dublin Institute for Advanced Studies, Dublin, Ireland.
- School of Physics, Trinity College Dublin, Dublin, Ireland.
| | | | | | - P J Kavanagh
- Dublin Institute for Advanced Studies, Dublin, Ireland
- Department of Experimental Physics, Maynooth University, Maynooth, Ireland
| | - K Justtanont
- Department of Space, Earth and Environment, Chalmers University of Technology, Onsala Space Observatory, Onsala, Sweden
| | | | - M Reitsma
- European Space Agency, ESTEC, Noordwijk, the Netherlands
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - H Beuther
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - L Francis
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - C Gieser
- Max-Planck-Institut für Extraterrestrische Physik, Garching, Germany
| | - P Klaassen
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| | - G Perotti
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - L Tychoniec
- European Southern Observatory, Garching, Germany
| | - M van Gelder
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - L Colina
- Centro de Astrobiología (CAB, CSIC-INTA), Carretera de Ajalvir, Torrejón de Ardoz, Spain
| | - Th R Greve
- DTU Space, Technical University of Denmark, Kongens Lyngby, Denmark
| | - M Güdel
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
- Department of Astrophysics, University of Vienna, Vienna, Austria
- ETH Zürich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - Th Henning
- Max-Planck-Institut für Astronomie (MPIA), Heidelberg, Germany
| | - P O Lagage
- Université Paris-Saclay, Université Paris Cité, CEA, CNRS, AIM, Gif-sur-Yvette, France
| | - G Östlin
- Department of Astronomy, Stockholm University, AlbaNova University Center, Stockholm, Sweden
| | | | - C Waelkens
- Institute of Astronomy, KU Leuven, Leuven, Belgium
| | - G Wright
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Perotti G, Christiaens V, Henning T, Tabone B, Waters LBFM, Kamp I, Olofsson G, Grant SL, Gasman D, Bouwman J, Samland M, Franceschi R, van Dishoeck EF, Schwarz K, Güdel M, Lagage PO, Ray TP, Vandenbussche B, Abergel A, Absil O, Arabhavi AM, Argyriou I, Barrado D, Boccaletti A, Caratti O Garatti A, Geers V, Glauser AM, Justannont K, Lahuis F, Mueller M, Nehmé C, Pantin E, Scheithauer S, Waelkens C, Guadarrama R, Jang H, Kanwar J, Morales-Calderón M, Pawellek N, Rodgers-Lee D, Schreiber J, Colina L, Greve TR, Östlin G, Wright G. Water in the terrestrial planet-forming zone of the PDS 70 disk. Nature 2023; 620:516-520. [PMID: 37488359 PMCID: PMC10432267 DOI: 10.1038/s41586-023-06317-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 06/13/2023] [Indexed: 07/26/2023]
Abstract
Terrestrial and sub-Neptune planets are expected to form in the inner (less than 10 AU) regions of protoplanetary disks1. Water plays a key role in their formation2-4, although it is yet unclear whether water molecules are formed in situ or transported from the outer disk5,6. So far Spitzer Space Telescope observations have only provided water luminosity upper limits for dust-depleted inner disks7, similar to PDS 70, the first system with direct confirmation of protoplanet presence8,9. Here we report JWST observations of PDS 70, a benchmark target to search for water in a disk hosting a large (approximately 54 AU) planet-carved gap separating an inner and outer disk10,11. Our findings show water in the inner disk of PDS 70. This implies that potential terrestrial planets forming therein have access to a water reservoir. The column densities of water vapour suggest in-situ formation via a reaction sequence involving O, H2 and/or OH, and survival through water self-shielding5. This is also supported by the presence of CO2 emission, another molecule sensitive to ultraviolet photodissociation. Dust shielding, and replenishment of both gas and small dust from the outer disk, may also play a role in sustaining the water reservoir12. Our observations also reveal a strong variability of the mid-infrared spectral energy distribution, pointing to a change of inner disk geometry.
Collapse
Affiliation(s)
- G Perotti
- Max Planck Institute for Astronomy, Heidelberg, Germany.
| | | | - Th Henning
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - B Tabone
- Université Paris-Saclay, CNRS, Institut d'Astrophysique Spatiale, Orsay, France
| | - L B F M Waters
- Department of Astrophysics/IMAPP, Radboud University, Nijmegen, the Netherlands
- SRON Netherlands Institute for Space Research, Leiden, the Netherlands
| | - I Kamp
- Kapteyn Astronomical Institute, Rijksuniversiteit Groningen, Groningen, the Netherlands
| | - G Olofsson
- Department of Astronomy, Stockholm University, AlbaNova University Center, Stockholm, Sweden
| | - S L Grant
- Max-Planck Institut für Extraterrestrische Physik (MPE), Garching, Germany
| | - D Gasman
- Institute of Astronomy, KU Leuven, Leuven, Belgium
| | - J Bouwman
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - M Samland
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - R Franceschi
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - E F van Dishoeck
- Max-Planck Institut für Extraterrestrische Physik (MPE), Garching, Germany
- Leiden Observatory, Leiden University, Leiden, the Netherlands
| | - K Schwarz
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - M Güdel
- Max Planck Institute for Astronomy, Heidelberg, Germany
- Dept. of Astrophysics, University of Vienna, Vienna, Austria
- ETH Zürich, Institute for Particle Physics and Astrophysics, Zürich, Switzerland
| | - P-O Lagage
- Université Paris-Saclay, Université Paris Cité, CEA, CNRS, AIM, Gif-sur-Yvette, France
| | - T P Ray
- Dublin Institute for Advanced Studies, Dublin, Ireland
| | | | - A Abergel
- Université Paris-Saclay, CNRS, Institut d'Astrophysique Spatiale, Orsay, France
| | - O Absil
- STAR Institute, Université de Liège, Liège, Belgium
| | - A M Arabhavi
- Kapteyn Astronomical Institute, Rijksuniversiteit Groningen, Groningen, the Netherlands
| | - I Argyriou
- Institute of Astronomy, KU Leuven, Leuven, Belgium
| | - D Barrado
- Centro de Astrobiología (CAB), CSIC-INTA, Villanueva de la Cañada, Spain
| | - A Boccaletti
- LESIA, Observatoire de Paris, Université PSL, CNRS, Sorbonne Université, Université de Paris, Meudon, France
| | - A Caratti O Garatti
- Dublin Institute for Advanced Studies, Dublin, Ireland
- INAF - Osservatorio Astronomico di Capodimonte, Napoli, Italy
| | - V Geers
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| | - A M Glauser
- ETH Zürich, Institute for Particle Physics and Astrophysics, Zürich, Switzerland
| | - K Justannont
- Chalmers University of Technology, Onsala Space Observatory, Onsala, Sweden
| | - F Lahuis
- SRON Netherlands Institute for Space Research, Groningen, the Netherlands
| | - M Mueller
- Kapteyn Astronomical Institute, Rijksuniversiteit Groningen, Groningen, the Netherlands
| | - C Nehmé
- Université Paris-Saclay, Université Paris Cité, CEA, CNRS, AIM, Gif-sur-Yvette, France
| | - E Pantin
- Université Paris-Saclay, Université Paris Cité, CEA, CNRS, AIM, Gif-sur-Yvette, France
| | - S Scheithauer
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - C Waelkens
- Institute of Astronomy, KU Leuven, Leuven, Belgium
| | - R Guadarrama
- Dept. of Astrophysics, University of Vienna, Vienna, Austria
| | - H Jang
- Department of Astrophysics/IMAPP, Radboud University, Nijmegen, the Netherlands
| | - J Kanwar
- Kapteyn Astronomical Institute, Rijksuniversiteit Groningen, Groningen, the Netherlands
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
- TU Graz, Fakultät für Mathematik, Physik und Geodäsie, Graz, Austria
| | - M Morales-Calderón
- Centro de Astrobiología (CAB), CSIC-INTA, Villanueva de la Cañada, Spain
| | - N Pawellek
- Dept. of Astrophysics, University of Vienna, Vienna, Austria
| | - D Rodgers-Lee
- Dublin Institute for Advanced Studies, Dublin, Ireland
| | - J Schreiber
- Max Planck Institute for Astronomy, Heidelberg, Germany
| | - L Colina
- Centro de Astrobiología (CAB, CSIC-INTA), Carretera de Ajalvir, Torrejón de Ardoz, Spain
| | - T R Greve
- DTU Space, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - G Östlin
- Department of Astronomy, Oskar Klein Centre, Stockholm University, Stockholm, Sweden
| | - G Wright
- UK Astronomy Technology Centre, Royal Observatory Edinburgh, Edinburgh, UK
| |
Collapse
|
5
|
Talenfeld C, Lansing A, Clarke K, Wright G, Lee D, Ghosh S, Raza S, Zhang Y, McClure T. Abstract No. 542 Microwave Ablation versus Cryoablation for T1a Renal Cell Carcinoma: A Systematic Literature Review and Meta-Analysis. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
|
6
|
Stirling R, Smith S, Brand M, Harden S, Briggs L, Leigh L, Brims F, Brooke M, Brunelli V, Chia C, Dawkins P, Lawrenson R, Duffy M, Evans S, Leong T, Marshall H, Patel D, Pavlakis N, Philip J, Rankin N, Singhal N, Stone E, Tay R, Vinod S, Windsor M, Wright G, Leong D, Zalcberg J. EP04.01-023 Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Ponce Lorenzo J, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn J, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. Ann Oncol 2022; 33:384-394. [PMID: 35093516 DOI: 10.1016/j.annonc.2022.01.009] [Citation(s) in RCA: 76] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 01/14/2022] [Accepted: 01/20/2022] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Primary analyses of the phase 3 BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from the trial. DESIGN Women with untreated stage II-III TNBC were randomized (2:1:1) to paclitaxel (weekly for 12 doses) plus either: (a) carboplatin (every 3 weeks for four cycles) plus veliparib (twice daily); (b) carboplatin plus veliparib placebo; or (c) carboplatin placebo plus veliparib placebo. All patients then received doxorubicin and cyclophosphamide (AC) every 2‒3 weeks for four cycles. The primary endpoint was pCR. Secondary endpoints included event-free survival (EFS), overall survival (OS), and safety. Since the co-primary endpoint of increased pCR with carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel was not met, secondary analyses are descriptive. RESULTS Of 634 patients, 316 were randomized to carboplatin plus veliparib with paclitaxel, 160 to carboplatin with paclitaxel, and 158 to paclitaxel. With median follow-up of 4.5 years, the hazard ratio [HR] for EFS for carboplatin plus veliparib with paclitaxel versus paclitaxel was 0.63 (95% confidence interval [CI] 0.43‒0.92, P=0.02), but 1.12 (95% CI 0.72‒1.72, P=0.62) for carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel. In post hoc analysis, HR for EFS was 0.57 (95% CI 0.36‒0.91, P=0.02) for carboplatin with paclitaxel versus paclitaxel. OS did not differ significantly between treatment arms, nor did rates of myelodysplastic syndromes, acute myeloid leukemia, or other secondary malignancies. CONCLUSION Improvement in pCR with addition of carboplatin was associated with long-term EFS benefit with a manageable safety profile, and without increasing the risk of second malignancies, while adding veliparib did not impact EFS. These findings support the addition of carboplatin to weekly paclitaxel followed by AC neoadjuvant chemotherapy for early stage TNBC.
Collapse
Affiliation(s)
- C E Geyer
- National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA; Houston Methodist Cancer Center, Houston, TX, USA.
| | - W M Sikov
- Women, Infants Hospital of Rhode Island, Providence, RI, USA
| | - J Huober
- Breast Center Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - H S Rugo
- University of California San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
| | - N Wolmark
- National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; Baylor University Medical Center, Dallas, TX, USA
| | - D Maag
- AbbVie Inc., North Chicago, IL, USA
| | - M Untch
- HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - M Golshan
- Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
| | - J Ponce Lorenzo
- University General Hospital of Alicante, ISABIAL, Alicante, Spain
| | - O Metzger
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M Dunbar
- AbbVie Inc., North Chicago, IL, USA
| | | | - P Rastogi
- National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA, USA; UPMC Hillman Cancer Center/University of Pittsburgh, Pittsburgh, PA, USA
| | - J Sohn
- Yonsei University College of Medicine, Seoul, Korea
| | - R Young
- Division of Breast Oncology, The Center for Cancer and Blood Disorders, Fort Worth, USA
| | - G S Wright
- Florida Cancer Specialists and Sarah Cannon Research Institute, New Port Richey, FL, USA
| | - C Harkness
- Hope Women's Cancer Centers, Asheville, NC, USA
| | - K McIntyre
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA
| | - D Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA
| | - S Loibl
- German Breast Group, c/o GBG Forschungs GmbH, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany
| |
Collapse
|
8
|
Cimpeanu O, Sim K, Lau Y, Dobson R, Marshall G, Padfield G, Wright G, Connelly D. Negative impact of socioeconomic deprivation on clinical outcomes after cryoablation for atrial fibrillation: 18-month study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Lower socioeconomic status has also been shown to associate with higher incidence of atrial fibrillation (AF), increased mortality and morbidity. However, the impact of socioeconomic deprivation on clinical outcomes post AF cryoablation has yet to be investigated.
Aim
To assess the impact of socioeconomic deprivation (as categorised by Scottish Index of Multiple Deprivation, SIMD) on the medical management and clinical outcomes of patients with AF post cryoablation.
Methods
A retrospective study of paroxysmal or persistent AF patients after cryoablation. Parameters included basic demographics, weight, past medical history (hypertension, heart failure, diabetes, stroke, myocardial infarction, sleep apnoea) and alcohol misuse. Medical treatment post ablation (Beta blocker, calcium channel blocker, flecainide, amiodarone, dronaderone, sotolol, anticoagulant use) were also recorded.
Socioeconomic deprivation index, as per SIMD was recorded (1 – most deprived and 10 – least deprived), and accordingly placed into quintile (SIMD 1–2,3–4,5–6,7–8, 9–10). Follow-up for 18 months.
Clinical outcome assessed was rate of readmission for symptomatic AF, rate of heart failure admission, stroke, bleeding diathesis and all-cause mortality.
Results
383 patients were identified: 78 from the lowest quintile (SIMD 1–2), 68 (SIMD 3–4), 64 (SIMD 5–6), 62 (SIMD 7–8), and 111 from the highest quintile (SIMD 9–10). No statistical difference exists between age, gender or weight. Lowest socioeconomic quintile has higher incidence of heart failure (p=0.006) and hypertension (p=0.005) but other past medical history was no different. No difference in incidence of alcohol misuse.
Medicine prescription was not different. Echo features: left ventricular function, atrial size and valvular dysfunction were not different between all groups.
18 months follow-up demonstrated that both readmission for symptomatic documented AF and recurrence of symptoms at 18 months were higher among patients of lowest socioeconomic quintile (Keplan Meier plot, p=0.014 and p=0.006 respectively). Stepwise multiple regression analysis also confirmed multiple socioeconomic deprivation as an independent predictor for more adverse clinical outcome (p=0.02).
Risk of symptom recurrence at 18 months in patients from the least deprived background is less than one third as compared to the ones from the most deprived background (Odd-ratio 0.32 (0.17 - 0.59))
Risk of readmission for AF in patients from the wealthiest socioeconomic group is also less than a third as compared to those of most deprived social group (Odd-ratio 0.31 (95% CI 0.15–0.61)).
Other clinical outcomes including risk of admissions for heart failure, stroke, bleeding diathesis and all-cause mortality was not statistically different across all groups.
Summary
After cryoablation, patients from the lowest socioeconomic group are more likely to experience symptoms recurrence and readmission for symptomatic AF
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- O Cimpeanu
- Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - K.Y.T Sim
- Queen Elizabeth University Hospital, Glasgow, United Kingdom
| | - Y Lau
- Golden Jubilee National Hospital, Glasgow, United Kingdom
| | - R Dobson
- Golden Jubilee National Hospital, Glasgow, United Kingdom
| | - G Marshall
- Glasgow Royal Infirmary, Glasgow, United Kingdom
| | - G Padfield
- Forth Valley Royal Hospital, Larbert, United Kingdom
| | - G Wright
- Golden Jubilee National Hospital, Glasgow, United Kingdom
| | - D.T Connelly
- Golden Jubilee National Hospital, Glasgow, United Kingdom
| |
Collapse
|
9
|
Gibofsky A, Dhillon B, Pearson ME, Tundia N, Song Y, Dunlap K, Wright G. POS0666 TREATMENT EFFECTIVENESS OF UPADACITINIB AT 3 MONTHS IN US PATIENTS WITH RHEUMATOID ARTHRITIS FROM THE UNITED RHEUMATOLOGY NORMALIZED INTEGRATED COMMUNITY EVIDENCE (NICE[TM]) REAL-WORLD DATA. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Upadacitinib (UPA), an oral Janus kinase inhibitor (JAKi), has demonstrated efficacy in the phase 3 SELECT clinical program, conducted across a range of patients (pts) with rheumatoid arthritis (RA).1–6 Real-world data for UPA, including in pts previously treated with a JAKi, have not yet been reported since global approvals beginning in 2019.Objectives:To assess the characteristics of US-based pts receiving UPA and its effectiveness in clinical practice at 3 months.Methods:This observational study included US-based pts from the United Rheumatology Normalized Integrated Community Evidence (UR-NICE) database who initiated UPA 15 mg once daily from FDA approval (August 2019) to July 31, 2020 and had ≥6-month pre-baseline data available. Effectiveness was assessed in pts with a reported Clinical Disease Activity Index (CDAI) score at 3 months after UPA initiation and included proportions of pts achieving CDAI remission (≤2.8), CDAI low disease activity (≤10), other disease activity measures, and pt-reported outcomes. A subgroup analysis assessed UPA effectiveness in pts with or without prior tofacitinib (TOFA) treatment.Results:This analysis included 252 pts treated with UPA 15 mg, of whom 98 (38.9%) received UPA monotherapy and 154 (61.1%) received UPA combined with conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs). 64.3% of pts were from the Southern region of the USA. 86.1%, 72.2%, and 47.6% of pts had been previously treated with csDMARDs, biologic DMARDs, and JAKis, respectively. Baseline characteristics were largely similar between UPA monotherapy and combination therapy groups and those with or without prior TOFA treatment (Table 1). Pts with prior TOFA treatment had a longer duration of RA since diagnosis and higher steroid use versus those without. UPA 15 mg improved disease activity scores (including CDAI) and pt-reported outcomes (including physical function and pain) after 3 months of treatment (Figure 1). Similar effectiveness was observed with UPA 15 mg in pts with or without prior TOFA treatment.Conclusion:In the UR-NICE real-world database of US-based pts, improvements in clinical and pt-reported outcomes were observed at 3 months in UPA-treated pts with RA, including those with or without prior TOFA treatment, despite the treatment-refractory population included in this dataset.References:[1]Burmester GR, et al. Lancet 2018;391:2503–12.[2]Smolen JS, et al. Lancet 2019;393:2303–11.[3]Fleischmann R, et al. Arthritis Rheumatol 2019;71:1788–800.[4]Genovese MC, et al. Lancet 2018;391:2513–24.[5]van Vollenhoven R, et al. Arthritis Rheumatol 2020;72:1607–20.[6]Rubbert-Roth A, et al. N Engl J Med 2020;383:1511–21.Table 1.Baseline characteristicsn (%), unless otherwise statedFull analysis set(n=252)Pts with prior TOFA treatment(n=113)Pts without prior TOFA treatment (n=139)Mean (SD) exposure, days219.7 (112.1)215.7 (116.7)222.9 (108.5)Female199 (79.0)85 (75.2)114 (82.0)Age ≥65 years75 (29.8)34 (30.1)41 (29.5)Oral steroid use140 (55.6)70 (61.9)70 (50.4)Prior csDMARDs217 (86.1)102 (90.3)115 (82.7)Prior TOFA113 (44.8)113 (100.0)0Prior biologic DMARDs182 (72.2)86 (76.1)96 (69.1)Tumor necrosis factor inhibitor147 (58.3)66 (58.4)81 (58.3)Interleukin-6 receptor inhibitor87 (34.5)47 (41.6)40 (28.8)nMean (SD)nMean (SD)nMean (SD)Duration of RA diagnosis, years1884.0 (3.0)895.1 (2.9)993.1 (2.8)Methotrexate dose, mg/week8817.0 (5.1)2817.8 (5.0)6016.6 (5.2)SJC282394.8 (5.7)1084.5 (5.0)1315.0 (6.2)TJC282376.5 (6.7)1076.5 (6.8)1306.5 (6.6)CDAI22520.4 (13.4)10520.2 (13.5)12020.6 (13.3)Routine assessment of patient index data 31654.2 (2.3)724.2 (2.4)934.3 (2.2)Disease Activity Score in 28 joints based on C-reactive protein1673.9 (1.5)833.9 (1.5)843.9 (1.5)Health Assessment Questionnaire-Disability Index1702.5 (2.1)742.4 (2.2)962.5 (2.1)Pain(0–10)22956.5 (28.5)10456.9 (29.3)12556.1 (28.0)SD, standard deviation; S/TJC, swollen/tender joint countAcknowledgements:AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and participated in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Hilary Wong, PhD, of 2 the Nth (Cheshire, UK), and was funded by AbbVie.Disclosure of Interests:Allan Gibofsky Shareholder of: AbbVie, Amgen, Johnson & Johnson, and Pfizer, Consultant of: AbbVie, Celgene, Eli Lilly, Flexion, Pfizer, Relburn Pharma, and Samumed. Paid consultant with investment analysts on behalf of the Gerson Lehrman Group, Bhavna Dhillon Shareholder of: May own stock or options in United Rheumatology, Employee of: United Rheumatology, Mark E. Pearson Shareholder of: May own AbbVie stock or options, Namita Tundia Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Yanna Song Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Kendall Dunlap Shareholder of: May own stocks or shares in AbbVie, Employee of: AbbVie, Grace Wright Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Exagen, Myriad Autoimmune, Novartis, Sanofi/Regeneron, UCB, and Vindico, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Exagen, Gilead, Janssen, Myriad Autoimmune, Novartis, Pfizer, Sanofi/Regeneron, and UCB, Employee of: President and Founder of the Association of Women in Rheumatology
Collapse
|
10
|
Best S, Ding S, Kersbergen A, Reljic B, Wright G, Rathi V, Desouza D, Mcconville M, Ritchie M, Sutherland K. P62.05 Identifying Therapeutic Approaches to Treat KEAP1-Mutant Lung Adenocarcinoma. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Stirling R, Brand M, Earnest A, Antippa P, Ball D, Bartlett J, Blum R, Briggs L, Caldecott M, Conron M, Jennings B, Langton D, Millar J, Mitchell P, Olesen I, Parente P, Richardson G, See K, Torres J, Underhill C, Wright G, Stenger M, Mcneil J, Zalcberg J. OA05.06 Lessons Learned from the Victorian Lung Cancer Registry: Opportunities for Quality Improvement in Lung Cancer Management and Outcomes. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Cheung F, Goldblatt J, Alam N, Wright G. R30 Return to Intended Oncologic Treatment (RIOT) Analysis Following Surgery for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.03.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Bass M, Jacknin G, Paavola N, Kiser T, Wright G. 359 Evaluation of Insulin Infusion Rates for the Treatment of Diabetic Ketoacidosis in the Emergency Department. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Weinblatt M, Mysler E, Ostor A, Broadwell A, Jeka S, Dunlap K, Suboticki J, Enejosa J, Hendrickson B, Zhong S, Cherny K, Wright G. FRI0140 IMPACT OF BASELINE DEMOGRAPHICS AND DISEASE ACTIVITY ON OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately to severely active rheumatoid arthritis (RA).1–5Objectives:This analysis reports the efficacy and safety of UPA in predefined RA patient subgroups based on differences in baseline demographics and disease activity.Methods:Data were pooled from three pivotal, double-blind, PBO-controlled, multicenter, Phase 3 studies in patients with RA who had an inadequate response(IR) to conventional synthetic DMARDs (csDMARD-IR: SELECT-NEXT [N=661]), MTX(MTX-IR; SELECT-COMPARE[N=1629]), or biologic DMARDs(bDMARD-IR: SELECT-BEYOND[N=498]). Two integrated analysis sets were evaluated: one comparing UPA 15 mg QD vs PBO(SELECT-NEXT, SELECT-COMPARE, SELECT-BEYOND) and the other comparing UPA 15 mg QD and UPA 30 mg QD vs PBO(SELECT-NEXT, SELECT-BEYOND). All patients received background treatment with csDMARDs. The proportion of patients achieving ACR20 and DAS28(CRP) ≤3.2 at Week 12 was evaluated by predefined baseline demographics and disease activity measure groups, including age, sex, weight, BMI, race, geographic region, duration of RA, RF, and ACPA status, and level of high sensitivity CRP. Non-responder imputation was used for missing data. Subgroup analyses for safety were performed for age, race, sex, weight, BMI, and Asian region.Results:Across the three Phase 3 studies, 1036, 384, and 1041 patients received UPA 15 mg QD, UPA 30 mg QD or PBO, respectively. The demographic and baseline disease characteristics in the two integrated analysis sets were balanced across treatment groups. ACR20 and DAS28 ≤3.2 response rates at Week 12 were consistently higher with UPA 15 mg and UPA 30 mg vs PBO across the evaluated demographic and baseline disease characteristics(Figure 1a,Figure 1b). The efficacy of UPA 15 mg QD was generally similar to that observed with UPA 30 mg QD. At 12 weeks, the proportion of patients with treatment-emergent AEs, serious AEs, severe AEs, and AEs leading to discontinuation were generally comparable across different age, sex, race, weight, and BMI groups. Compared with the global population, patients receiving UPA in the Asian region had a higher rate of CPK elevations(UPA 30 mg only) and herpes zoster; herpes zoster also has been observed to be higher in the Asian region with other JAK inhibitors.6,7Conclusion:In this analysis of pooled integrated efficacy data in csDMARD-IR or bDMARD-IR patients with RA, UPA 15 mg or 30 mg QD in combination with csDMARDs improved efficacy outcomes at Week 12 when compared with PBO across all predefined subgroups evaluated.References:[1]Burmester GR, et al. Lancet 2018 23;391:2503–2512;[2]Genovese MC, et al. Lancet 2018; 391:2513–24;[3]Smolen JS, et al. Lancet 2019 May 23[Epub ahead of print];[4]van Vollenhoven R, et al. Arthritis Rheumatol 2018;70(Suppl. 10): Abstract 891;[5]Fleischmann R, et al. Arthritis Rheumatol 2018;70(Suppl. 10): Abstract 890;[6]Winthrop KL, et al. Arthritis Rheum 2014;66:2675-84;[7] Winthrop KL, et al. ACR 2016 [Abstract 3027]Disclosure of Interests:Michael Weinblatt Grant/research support from: Amgen, Bristol-Myers Squibb, Crescendo, Lily, Sanofi/Regeneron, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Gilead, Horizon, Lily, Pfizer, Roche, Eduardo Mysler Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Roche, Eli Lilly, Novartis, Janssen, Sanofi, and Pfizer., Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Roche, Eli Lilly, Novartis, Janssen, Sanofi, and Pfizer, Andrew Ostor Consultant of: MSD, Pfizer, Lilly, Abbvie, Novartis, Roche, Gilead and BMS, Speakers bureau: MSD, Pfizer, Lilly, Abbvie, Novartis, Roche, Gilead and BMS, Aaron Broadwell Grant/research support from: Janssen Research & Development, LLC, Janssen, Eli Lilly, Consultant of: AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, Speakers bureau: AbbVie, Amgen, Celgene, GSK, Horizon, Janssen, Mallinckrodt, Novartis, Pfizer, Radius, Sanofi-Regeneron, UCB, Sławomir Jeka Grant/research support from: AbbVie, Pfizer, Roche, Novartis, MSD, Sandoz, Eli Lilly, Egis, UCB, Celgene, Speakers bureau: AbbVie, Pfizer, Roche, Novartis, MSD, Sandoz, Eli Lilly, Egis, UCB, Celgene, Kendall Dunlap Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Jessica Suboticki Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Jeffrey Enejosa Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Barbara Hendrickson Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Sheng Zhong Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Katya Cherny Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Grace Wright Consultant of: AbbVie, Amgen, BMS, Exagen, Janssen, Lilly, Medac, Myriad Autoimmune, Novartis, Pfizer, Sanofi Genzyme Regeneron, and UCB, Speakers bureau: AbbVie, Amgen, BMS, Exagen, Lilly, Medical Education Resource, Myriad Autoimmune, Novartis, Sanofi Genzyme Regeneron, UCB, and Vindico
Collapse
|
15
|
Sokol G, Loftus L, Oliver T, Ajub J, Wright G, Wenk D. GERIATRIC SKIN CANCER AND CONCOMITANT PHOTOSENSITIVITY DRUG UTILIZATION. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31177-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Wright G. CS01.04 NSCLC OMD is Defined by a Fixed Maximum Number of Metastases, Not Technical Reasons of Local Treatment. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 2019; 10:3407. [PMID: 31431620 PMCID: PMC6702229 DOI: 10.1038/s41467-019-11276-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 07/02/2019] [Indexed: 02/06/2023] Open
Abstract
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.
Collapse
Affiliation(s)
- N Alcala
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - N Leblay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A A G Gabriel
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Mangiante
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - D Hervas
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - T Giffon
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A S Sertier
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - A Ferrari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - J Derks
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - A Ghantous
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - T M Delhomme
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Chabrier
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Cuenin
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - B Abedi-Ardekani
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Boland
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - R Olaso
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - V Meyer
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - J Altmuller
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
| | - F Le Calvez-Kelm
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - G Durand
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Voegele
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - S Boyault
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
| | - L Moonen
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Lemaitre
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - P Lorimier
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - A C Toffart
- Pulmonology-Physiology Unit, Grenoble Alpes University Hospital, 38700, La Tronche, France
| | - A Soltermann
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
| | - J H Clement
- Department Hematology and Medical Oncology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany
| | - J Saenger
- Bad Berka Institute of Pathology, Robert-Koch-Allee 9, 99438, Bad Berka, Germany
| | - J K Field
- Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 6 West Derby Street, L7 8TX, Liverpool, UK
| | - M Brevet
- Pathology Institute, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 59 Boulevard Pinel, 69677, BRON Cedex, France
| | - C Blanc-Fournier
- CLCC François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France
| | - F Galateau-Salle
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - N Le Stang
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - P A Russell
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Wright
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Sozzi
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - U Pastorino
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - S Lacomme
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - J M Vignaud
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - O T Brustugun
- Drammen Hospital, Vestre Viken Health Trust, Vestre Viken HF, Postboks 800, 3004, Drammen, Norway
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | - M Lund-Iversen
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | | | - L A Muscarella
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - P Graziano
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - H Popper
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - J Stojsic
- Department of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Pasterova 2, Belgrade, 11000, Serbia
| | - J F Deleuze
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - Z Herceg
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Viari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - P Nuernberg
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Straße 26, 50931, Cologne, Germany
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy
| | - A M C Dingemans
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - M Milione
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Roz
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - M Volante
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - M G Papotti
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - C Caux
- Department of Immunity, Virus, and Inflammation, Cancer Research Centre of Lyon (CRCL), 28 Rue Laennec, 69008, Lyon, France
| | - J Sandoval
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - H Hernandez-Vargas
- Cancer Research Centre of Lyon (CRCL), Inserm U 1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, 28 Rue Laennec, 69008, Lyon, France
| | - E Brambilla
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - E J M Speel
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Girard
- Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
- European Reference Network (ERN-EURACAN), 28 rue Laennec, 69008, Lyon, France
| | - S Lantuejoul
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - J D McKay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - M Foll
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Fernandez-Cuesta
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France.
| |
Collapse
|
18
|
O'Shaughnessy J, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Cheung E, Han HS, Daniel BR, Vojnovic Z, Vasev N, Ling M, Richards DA, Wilks ST, Milenkovic D, Sorrentino JA, Roberts PJ, Bomar M, Yang Z, Antal JM, Malik RK, Morris SR, Tan A. Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cytotoxic chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPCs) results in acute toxicities consisting of multi-lineage myelosuppression, and late onset toxicities consisting of progressive bone marrow suppression with increased incidence of therapy-related myeloid neoplasms. T is an IV CDK4/6 inhibitor in development to preserve HSPC and immune system function during cytotoxic chemotherapy (myelopreservation). Proof of concept for myelopreservation with T was observed in a randomized, placebo-controlled Phase 2 trial in small-cell lung cancer patients receiving 1st-line chemotherapy. This trial in mTNBC patients (NCT02978716) was designed to explore the utility of T in combination with GC.
Methods: This Phase 2, randomized, open-label study enrolled patients in the US and EU with mTNBC who had received 0-2 prior systemic cytotoxic therapies in the locally recurrent or metastatic setting and had no symptomatic brain metastases. Patients were randomized (1:1:1) to GC alone (Group 1) or T plus GC (Group 2) using a standard schedule (D1, 8 every 21 days) or to an alternative schedule (T on D1, 2, 8 and 9 with GC on D2 and 9 every 21 days; Group 3). On those days when both T and GC were scheduled, T was administered iv prior to GC infusion. Prophylactic growth factors were not administered in cycle 1; otherwise supportive care was allowed as needed. Primary objectives were safety and tolerability; tumor response was evaluated using RECIST v1.1 and PFS and OS were assessed. Myelopreservation endpoints reflecting the potential effects of T on multiple cellular lineages include occurrence of Grade 4 neutropenia (primary), RBC and platelet transfusions (primary), and lymphocyte counts with immune profiling (secondary and exploratory). A signature of CDK4/6 independence developed from preclinical data will be used to evaluate archival tumor tissue samples and data analysis is ongoing.
Results: 95 patients were dosed; median age 57 years (range 32,86), ECOG PS 0 (53%) or 1 (47%), 25% had liver metastases at baseline, and approximately 50% had received no systemic therapy in the recurrent/metastatic setting. Fifty-five patients remain on treatment. Disease progression was the most common reason for drug discontinuation (22/40; 55%). Overall the most common (≥ 25%) TEAEs were anemia (47%), nausea (35%), fatigue (34%), neutropenia (32%), platelet count decreased (25%), and vomiting (25%). The most frequent (≥ 15%) Grade 3 or 4 TEAEs were hematologic toxicities, i.e. neutropenia (28%), anemia (21%), neutrophil count decreased (21%) and thrombocytopenia (16%). These were also the most frequent drug-related TEAEs observed. Tumor efficacy data are being evaluated.
Conclusions: This trial, assessing the myelopreservation effects of T when combined with GC in patients with mTNBC, has completed enrollment. Myelopreservation data, immune profiling, as well as ORR and preliminary PFS results will be presented by study arm at the meeting.
Citation Format: O'Shaughnessy J, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Cheung E, Han HS, Daniel BR, Vojnovic Z, Vasev N, Ling M, Richards DA, Wilks ST, Milenkovic D, Sorrentino JA, Roberts PJ, Bomar M, Yang Z, Antal JM, Malik RK, Morris SR, Tan A. Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-01.
Collapse
Affiliation(s)
- J O'Shaughnessy
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - GS Wright
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - AR Thummala
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - MA Danso
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - L Popovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - TJ Pluard
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - E Cheung
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - HS Han
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - BR Daniel
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - Z Vojnovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - N Vasev
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - M Ling
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - DA Richards
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - ST Wilks
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - D Milenkovic
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - JA Sorrentino
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - PJ Roberts
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - M Bomar
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - Z Yang
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - JM Antal
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - RK Malik
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - SR Morris
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| | - A Tan
- Texas Oncology Baylor Sammons, US Oncology Research, Dallas, TX; Florida Cancer Specialists (North), Saint Petersburg, FL; Comprehensive Cancer Centers of Nevada, US Oncology Research, Las Vegas, NV; Virginia Oncology Specialists, US Oncology Research, Norfolk, VA; Oncology Institute of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; Saint Luke's Cancer Institute, Kansas City, MO; Innovative Clinical Research Institute, Whittier, CA; Moffitt Cancer Center, Tampa, FL; Tennessee Oncology – Chattanooga, Chattanooga, TN; County Hospital Varazdin, Varaždin, Croatia; University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of; Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO; Texas Oncology Tyler, US Oncology Research, Tyler, TX; Texas Oncology San Antonio Northeast, US Oncology Research, San Antonio, TX; Clinical Center Nis, Clinic of Oncology, Niš, Serbia; G1 Therapeutics, Research Triangle Park, NC; Levine Cancer Institute, Atrium Health, Charlo
| |
Collapse
|
19
|
Burgess J, Bolderson E, Adams M, Zhang S, Fox S, Wright G, Young R, Solomon B, Gray S, Richard D, O’Byrne K. Chloropyramine increases NSCLC sensitivity to cisplatin in a SASH1 dependent manner. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30046-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Eckhaus J, Kunz S, Wright G, Knight S. Validating In Training Assessment Profile (iTAP): A Score to Predict Postoperative Survival of Patients Undergoing Surgical Pleurodesis. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.02.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
21
|
Shukla A, Wright G, Denehy L, Granger C. Prehabilitation for Individuals Having Lung Cancer Surgery. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Addy C, Doran G, Jones AL, Wright G, Caskey S, Downey DG. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med 2018; 18:170. [PMID: 30453935 PMCID: PMC6245610 DOI: 10.1186/s12890-018-0732-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 10/29/2018] [Indexed: 11/30/2022] Open
Abstract
Background Non-Tuberculous Mycobacterial–pulmonary disease (NTM-PD) is increasing in incidence and prevalence. Mycobacterium abscessus (M.abscessus) is a rapid growing multi-resistant NTM associated with severe NTM-PD requiring prolonged antibiotic therapy. Complications of therapy are common but reports on direct complications of active NTM-PD are rare. Vasculitis has been described as a rare complication of NTM-PD, most often in individuals with inherited immune defects. This case is the first to describe an ANCA positive vasculitide (Microscopic Polyangiitis) secondary to M.abscessus pulmonary disease. Case presentation A 70 year old female with bronchiectasis underwent a clinical decline associated with the growth of M.abscessus and was diagnosed with NTM-PD. Before treatment could be initiated she developed small joint arthralgia and a glove and stocking axonal loss sensorimotor neuropathy. Positive Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) and Myeloperoxidase-ANCA (MPO-ANCA) titres led to a diagnosis of microscopic polyangiitis. Further investigation revealed reduced interferon-gamma production but no other significant immune dysfunction. Dual treatment with immunosuppressive therapy (Corticosteroids/Cyclophosphamide) for vasculitis and antimicrobial therapy for M.abscessus NTM-PD was initiated. Clinical stability was difficult to achieve with reductions in immunosuppression triggering vasculitic flares. One flare led to retinal vein occlusion with impending visual loss requiring escalation in immunosuppression to Rituximab infusions. An increase in immunosuppression led to a deterioration in NTM-PD necessitating alterations to antibiotic regimes. Adverse effects including alopecia and Achilles tendonitis have further limited antibiotic choices resulting in a strategy of pulsed intra-venous therapy to stabilise NTM-PD. Conclusions This is the first reported case of an ANCA positive vasculitis secondary to M.abscessus pulmonary disease. This rare but important complication had a significant impact on the patient adding to the complexity of an already significant disease and treatment burden. The potential role of reduced interferon-gamma production in this case highlights the importance of investigating immune function in those with mycobacterial infection and the intricate relationship between mycobacterial infection and immune dysfunction. Immune dysfunction caused by genetic defects or immunosuppressive therapy is a known risk factor for NTM-PD. Balancing immunosuppressive therapy with prolonged antimicrobial treatment is challenging and likely to become more common as the number of individuals being treated with biologics and immunosuppressive agents increases.
Collapse
Affiliation(s)
- C Addy
- Centre for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland. .,Regional Respiratory Centre, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB, Northern Ireland.
| | - G Doran
- Regional Respiratory Centre, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB, Northern Ireland
| | - A L Jones
- Department of Respiratory Medicine, Royal Brompton Hospitals, Sydney Street, London, SW3 6NP, England
| | - G Wright
- Department of Rheumatology, Musgrave Park Hospital, Stockmans Ln, Belfast, BT9 7JB, Northern Ireland
| | - S Caskey
- Regional Respiratory Centre, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB, Northern Ireland
| | - D G Downey
- Centre for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland.,Regional Respiratory Centre, Belfast City Hospital, 51 Lisburn Road, Belfast, BT9 7AB, Northern Ireland
| |
Collapse
|
23
|
Mitchell A, Wright G, Sampson SN, Martin M, Cummings K, Gaddy D, Watts AE. Clodronate improves lameness in horses without changing bone turnover markers. Equine Vet J 2018; 51:356-363. [DOI: 10.1111/evj.13011] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 08/20/2018] [Indexed: 12/18/2022]
Affiliation(s)
- A. Mitchell
- Department of Large Animal Clinical Sciences Cornell University Ithaca New York USA
| | - G. Wright
- Department of Veterinary Pathobiology Cornell University Ithaca New York USA
| | - S. N. Sampson
- Department of Large Animal Clinical Sciences Cornell University Ithaca New York USA
| | - M. Martin
- Department of Large Animal Clinical Sciences Cornell University Ithaca New York USA
| | - K. Cummings
- Department of Population Medicine and Diagnostic Sciences Cornell University Ithaca New York USA
| | - D. Gaddy
- Department of Veterinary Integrative Biosciences Texas A&M University College Station Texas USA
| | - A. E. Watts
- Department of Large Animal Clinical Sciences Cornell University Ithaca New York USA
| |
Collapse
|
24
|
Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, Ferguson C, Handforth C, Joseph L, Mokhtar D, White L, Wright G, Henry A. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol) 2018; 30:548-555. [DOI: 10.1016/j.clon.2018.06.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/16/2018] [Accepted: 05/20/2018] [Indexed: 01/04/2023]
|
25
|
Schmuhl H, Marcelo A, Dal Molin J, Wright G, Karopka T. Towards Open Collaborative Health Informatics - The Role of Free/Libre Open Source Principles. Yearb Med Inform 2018. [DOI: 10.1055/s-0038-1638740] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
SummaryTo analyze the contribution of Free/Libre Open Source Software in health care (FLOSS-HC) and to give perspectives for future developments.The paper summarizes FLOSS-related trends in health care as anticipated by members of the IMIA Open Source Working Group. Data were obtained through literature review and personal experience and observations of the authors in the last two decades. A status quo is given by a frequency analysis of the database of Medfloss.org, one of the world’s largest platforms dedicated to FLOSS-HC. The authors discuss current problems in the field of health care and finally give a prospective roadmap, a projection of the potential influences of FLOSS in health care.FLOSS-HC already exists for more than 2 decades. Several projects have shown that FLOSS may produce highly competitive alternatives to proprietary solutions that are at least equivalent in usability and have a better total cost of ownership ratio. The Medfloss.org database currently lists 221 projects of diverse application types.FLOSS principles hold a great potential for addressing several of the most critical problems in health care IT. The authors argue that an ecosystem perspective is relevant and that FLOSS principles are best suited to create health IT systems that are able to evolve over time as medical knowledge, technologies, insights, workflows etc. continuously change. All these factors that inherently influence the development of health IT systems are changing at an ever growing pace. Traditional models of software engineering are not able to follow these changes and provide up-to-date systems for an acceptable cost/value ratio. To allow FLOSS to positively influence Health IT in the future a "FLOSS-friendly" environment has to be provided. Policy makers should resolve uncertainties in the legal framework that disfavor FLOSS. Certification procedures should be specified in a way that they do not raise additional barriers for FLOSS.
Collapse
|
26
|
|
27
|
Bardia A, Yardley DA, Hurvitz S, Wright G, Moroose R, Ma C, Hart L, Tan-Chiu E, Blau S, Sanft T, Dichmann R, Zelnak A, DeMichele A, Clark A, Small T, Tucci C, Samant TS, Purkayastha D, Karuturi M, Moulder S. Abstract PD5-11: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd5-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- A Bardia
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - DA Yardley
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Hurvitz
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - G Wright
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Moroose
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Hart
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Tan-Chiu
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Blau
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Sanft
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - R Dichmann
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Zelnak
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A DeMichele
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Clark
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - T Small
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Tucci
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - TS Samant
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - D Purkayastha
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - M Karuturi
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Moulder
- Massachusetts General Hospital Cancer Center, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; University of California, Los Angeles Medical Center, Santa Monica, CA; Florida Cancer Specialists, New Port Richey, FL; UF Health Cancer Center - Orlando Health, Orlando, FL; Washington University School of Medicine, St. Louis, MO; Florida Cancer Specialists and Research Institute, Fort Myers, FL; Florida Cancer Care, Plantation, FL; Northwest Medical Specialties, Puyallup, WA; Yale School of Medicine Smilow Cancer Hospital, New Haven, CT; Central Coast Medical Oncology Corporation, Santa Maria, CA; Atlanta Cancer Care (Northside Hospital), Cumming, GA; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
28
|
Brown SH, Wright G, Elkin PL. Biomedical Informatics: We Are What We Publish. Methods Inf Med 2018; 52:538-46. [DOI: 10.3414/me13-01-0041] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 08/07/2013] [Indexed: 11/09/2022]
Abstract
SummaryIntroduction: This article is part of a For-Discussion-Section of Methods of Information in Medicine on “Biomedical Informatics: We are what we publish“. It is introduced by an editorial and followed by a commentary paper with invited comments. In subsequent issues the discussion may continue through letters to the editor.Objective: Informatics experts have attempted to define the field via consensus projects which has led to consensus statements by both AMIA. and by IMIA. We add to the output of this process the results of a study of the Pubmed publications with abstracts from the field of Biomedical Informatics.Methods: We took the terms from the AMIA consensus document and the terms from the IMIA definitions of the field of Biomedical Informatics and combined them through human review to create the Health Infor -matics Ontology. We built a terminology server using the Intelligent Natural Language Processor (iNLP). Then we downloaded the entire set of articles in Medline identified by searching the literature by “Medical Informatics” OR “Bioinformatics”. The articles were parsed by the joint AMIA / IMIA terminology and then again using SNOMED CT and for the Bioinformatics they were also parsed using HGNC Ontology.Results: We identified 153,580 articles using “Medical Informatics” and 20,573 articles using “Bioinformatics”. This resulted in 168,298 unique articles and an overlap of 5,855 articles. Of these 62,244 articles (37%) had titles and abstracts that contained at least one concept from the Health Infor -matics Ontology. SNOMED CT indexing showed that the field interacts with most all clinical fields of medicine.Conclusions: Further defining the field by what we publish can add value to the consensus driven processes that have been the mainstay of the efforts to date. Next steps should be to extract terms from the literature that are uncovered and create class hierarchies and relationships for this content. We should also examine the high occurring of MeSH terms as markers to define Biomedical Informatics. Greater understanding of the Biomedical Informatics Literature has the potential to lead to improved self-awareness for our field.
Collapse
|
29
|
Dobrovic A, Do H, Wright G. P1.02-012 Profiling DNA Repair in Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
Goldblatt J, Alam N, Davies R, Lovell J, Wright G. P3.16-045 Evaluation of the Safety and Efficacy of VATS Pneumonectomy in the Treatment of Locally Advanced Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Donovan D, Buchenauer D, Whaley J, Wright G, Parish C, Hu X. Characterization of He-induced Bubble Formation in Tungsten due to Exposure from an Electron Cyclotron Resonance Plasma Source. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1333856] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- D. Donovan
- University of Tennessee-Knoxville, 1004 Estabrook Road, Knoxville, Tennessee 37996
| | - D. Buchenauer
- Sandia National Laboratory, 7011 East Avenue, Livermore, California 94550
| | - J. Whaley
- Sandia National Laboratory, 7011 East Avenue, Livermore, California 94550
| | - G. Wright
- Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139
| | - C.M. Parish
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831
| | - X. Hu
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831
| |
Collapse
|
32
|
Young R, Phelan J, Webster D, Roulland S, Wright G, Huang D, Schmitz R, Staudt L. CRISPR-CAS9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R.M. Young
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - J.D. Phelan
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - D.E. Webster
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - S. Roulland
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - G. Wright
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - D. Huang
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - R. Schmitz
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| | - L.M. Staudt
- Lymphoid Malignancies Branch; National Cancer Institute; Bethesda Maryland USA
| |
Collapse
|
33
|
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia 2017; 31:1087-1095. [PMID: 28126984 DOI: 10.1038/leu.2017.39] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 11/21/2016] [Accepted: 01/05/2017] [Indexed: 12/23/2022]
Abstract
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS). Instead, we studied the use of donor Epstein-Barr virus-specific T-cells (EBV CTL) transduced with a first generation CD19CAR, relying on the endogenous T-cell receptor for proliferation. We conducted a multi-center phase I/II study of donor CD19CAR transduced EBV CTL in pediatric acute lymphoblastic leukaemia (ALL). Patients were eligible pre-emptively if they developed molecular relapse (>5 × 10-4) post first stem cell transplant (SCT), or prophylactically post second SCT. An initial cohort showed poor expansion/persistence. We therefore investigated EBV-directed vaccination to enhance expansion/persistence. Eleven patients were treated. No CRS, neurotoxicity or graft versus host disease (GVHD) was observed. At 1 month, 5 patients were in CR (4 continuing, 1 de novo), 1 PR, 3 had stable disease and 3 no response. At a median follow-up of 12 months, 10 of 11 have relapsed, 2 are alive with disease and 1 alive in CR 3 years. Although CD19CAR CTL expansion was poor, persistence was enhanced by vaccination. Median persistence was 0 (range: 0-28) days without vaccination compared to 56 (range: 0-221) days with vaccination (P=0.06). This study demonstrates the feasibility of multi-center studies of CAR T cell therapy and the potential for enhancing persistence with vaccination.
Collapse
MESH Headings
- Antigens, CD19
- Child
- Child, Preschool
- Chimera
- Female
- Herpesvirus 4, Human
- Humans
- Immunotherapy/methods
- Immunotherapy, Adoptive
- Male
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/immunology
- Recurrence
- T-Lymphocytes, Cytotoxic/transplantation
- T-Lymphocytes, Cytotoxic/virology
- Vaccination
Collapse
Affiliation(s)
- C Rossig
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Pule
- Department of Haematology, Cancer Institute, University College London, London, UK
| | - B Altvater
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - S Saiagh
- Unite de Therapie Cellulaire et Genetique, CHU Nantes, Nantes, France
| | - G Wright
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - S Ghorashian
- Molecular and Cellular Immunology Section, Institute of Child Health, University College London, London, UK
| | | | - K Champion
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - Z Sattar
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - B Popova
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - A Hackshaw
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - P Smith
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - T Roberts
- Cancer Research UK and UCL Cancer Trials Centre, London, UK
| | - E Biagi
- Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy
| | - B Dreno
- Unite de Therapie Cellulaire et Genetique, CHU Nantes, Nantes, France
| | - R Rousseau
- Department of Pediatric Haemato-Oncology, Centre Leon Berard, Lyon, France
| | - S Kailayangiri
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Ahlmann
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - R Hough
- Department of Haematology, Cancer Institute, University College London, London, UK
| | - B Kremens
- Department of Pediatric Hematology and Oncology, University Children's Hospital Essen, Essen, Germany
| | - M G Sauer
- Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
| | - P Veys
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - N Goulden
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
| | - M Cummins
- Department of Bone Marrow Transplant, Bristol Royal Hospital for Children, Bristol, UK
| | - P J Amrolia
- Department of Paediatric Haematology and Bone Marrow Transplant, Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK
- Molecular and Cellular Immunology Section, Institute of Child Health, University College London, London, UK
| |
Collapse
|
34
|
O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. Abstract P4-22-04: A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Systemic inflammation is associated with poor prognosis in pts with ABC. The JAK/STAT pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. We evaluated the efficacy and safety of RUX, a JAK1/JAK2 inhibitor, plus CAPE in pts with HER2-negative ABC and high systemic inflammation defined by the modified Glasgow Prognostic Score (mGPS). Methods: In this double-blind phase 2 trial, pts were randomized 1:1 to 21 day cycles of RUX+CAPE or PBO+CAPE: RUX 15 mg or PBO PO BID for 21 d; CAPE 1000 mg/m2 PO BID for 14 d. Key inclusion criteria were systemic inflammation by mGPS of 1 or 2 (ie, CRP >10 mg/L), ECOG performance status ≤2, ≤2 prior chemotherapy regimens, and no prior CAPE. The primary endpoint was overall survival (OS); key secondary endpoints were progression-free survival (PFS), objective response rate (ORR; complete [CR] + partial response [PR]) per RECIST v1.1, clinical benefit rate (CBR; CR + PR + stable disease for ≥6 mo), duration of response, and safety. Treatment differences in OS and PFS were analyzed by the log-rank test; HRs and CIs were analyzed by the Cox proportional hazards model. Results: Baseline characteristics were similar between pts randomized to RUX+CAPE (n=76) vs PBO+CAPE (n=73): mGPS status (1, 82.9% vs 83.6%), hormone receptor (HR) status (positive, 67.1% vs 63.0%), and number of prior chemotherapy regimens for ABC (0, 50.0% vs 50.7%; 1, 38.2% vs 34.2%; 2, 9.2% vs 13.7%). Median treatment durations were 85 d with RUX in the RUX+CAPE group and 65 d with PBO in the PBO+CAPE group. Median OS was 11.2 mo with RUX+CAPE vs 10.9 mo with PBO+CAPE (HR, 0.932; 95% CI, 0.59–1.46; P=0.762). Median OS was 6.1 mo with RUX+CAPE vs 5.5 mo with PBO+CAPE in HR-negative pts and 11.7 mo and 12.2 mo in HR-positive pts. Median PFS was 4.5 mo with RUX+CAPE and 2.5 mo with PBO+CAPE (HR, 0.737; 95% CI, 0.49–1.12; P=0.151). Median PFS was 2.1 mo with RUX+CAPE vs 2.2 mo with PBO+CAPE in HR-negative pts and 6.1 mo and 4.1 mo in HR-positive pts. ORRs were 28.9% and 13.7% (P=0.024) in the RUX+CAPE and PBO+CAPE arms, respectively. The CBRs were 13.2% and 6.8%, respectively (P=0.278). Worsening of hematologic toxicity was higher and rates of grade 3/4 palmar-plantar erythrodysethesia (PPE) were lower (1.4% vs 12.7%, respectively) with RUX+CAPE (Table).
Safety RUX+CAPE (n=71)PBO+CAPE (n=71)%All-GradeGrade 3/4All-GradeGrade 3/4Nonhematologic Adverse Event*Fatigue56.35.643.74.2Nausea54.98.549.35.6Diarrhea47.98.526.82.8PPE46.51.438.012.7Vomiting38.05.629.64.2Hypokalemia15.58.57.02.8Worsening of Hematologic Toxicity†Anemia80.323.956.37.0Lymphopenia40.815.545.112.7Neutropenia39.411.322.52.8Thrombocytopenia39.411.315.51.4*Most common all-grade (≥35%) or grade 3/4 (≥5%) events in the RUX+CAPE arm (safety group). †Laboratory abnormalities.
Conclusion: These data support the prognostic capabilities of the mGPS. The addition of RUX to CAPE for pts with ABC and high systemic inflammation was associated with an improved ORR compared with PBO+CAPE, but did not improve OS or PFS.
Citation Format: O'Shaughnessy J, DeMichele A, Ma C, Richards P, Yardley DA, Wright G, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo H. A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-04.
Collapse
Affiliation(s)
- J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - A DeMichele
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - C Ma
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - P Richards
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - DA Yardley
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Wright
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - K Kalinsky
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Steis
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - S Diab
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - G Kennealey
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - R Geschwindt
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - W Jiang
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| | - H Rugo
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; University of Pennsylvania, Philadelphia, PA; Washington University School of Medicine, St Louis, MO; Oncology & Hematology Associates of Southwest Virginia, Inc, Salem, VA; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Florida Cancer Specialists, St Petersburg, FL; Columbia University Medical Center, New York, NY; Northside Hospital, Inc, Atlanta, GA; Rocky Mountain Cancer Centers, Aurora, CO; Incyte Corporation, Wilmington, DE; University of California, San Francisco, CA
| |
Collapse
|
35
|
Crochiere M, Vergote I, Lund B, Havsteen H, Ujmajuridze Z, Van Nieuwenhuysen E, Haslund C, Juhler-Nøttrup T, Mau-Sørensen M, Berteloot P, Kranich A, Meade J, Wright G, Shacham E, Rashal T, Saint-Martin JR, Shacham S, Kauffman M, Mirza MR, Landesman Y. Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Vergote I, Lund B, Havsteen H, Ujmajuridze Z, Van Nieuwenhuysen E, Haslund C, Juhler-Nøttrup T, Neven P, Mau-Sørensen M, Berteloot P, Kranich A, Rashal T, Meade J, Landesman Y, Saint-Martin JR, Wright G, Crochiere M, Shacham S, Kauffman M, Raza Mirza M. Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Ramaswamy L, Velraja S, Escalante G, Harvey P, Alencar M, Haddock B, Harvey P, Escalante G, Alencar M, Haddock B, Durkalec-Michalski K, Jeszka J, Zawieja B, Podgórski T, Trussardi Fayh AP, Okano AH, de Jesus Ferreira AM, Jäger R, Purpura M, Harris RC, Krause MM, Lavanger KA, Allen NO, Lieb AE, Mullen KA, Eckerson JM, Lavanger KA, Krause MM, Allen NO, Lieb AE, Mullen KA, Eckerson JM, Morales E, Forsse J, Andre T, McKinley S, Hwang P, Tinsley G, Spillane M, Grandjean P, Willoughby D, Jagim A, Wright G, Kisiolek J, Meinking M, Ochsenwald J, Andre M, Jones MT, Oliver JM, Ferreira VA, de Souza DC, dos Santos VOA, Browne RAV, Costa EC, Fayh APT, Mathews ST, Bishop HD, Bowen CR, Liang Y, West EA, Rogers RR, Marshall MR, Petrella JK, Holland AM, Kephart WC, Mumford PW, Mobley CB, Lowery RP, Wilson JM, Roberts MD, Trexler ET, Hirsch KR, Campbell BI, Mock MG, Smith-Ryan AE, Zemek K, Johnston C, Mobley CB, Mumford PW, Pascoe DD, Lockwood CM, Miller ME, Roberts MD, Sanders GJ, Peveler W, Warning B, Peacock CA, Kephart WC, Mumford PW, Lowery RP, Roberts MD, Wilson JM, Sandler D, Ojalvo SP, Komorowski J, Campbell BI, Aguilar D, Vargas A, Conlin L, Sanders A, Fink-Irizarry P, Norton L, Perry R, McCallum R, Wynn MR, Lenton J, Campbell BI, Gai C, Donelson S, Best S, Bove D, Couvillion K, Dolan J, Xing D, Chernesky K, Pawela M, Toledo AD, Jimenez R, Rabideau M, Walker A, Pellegrino J, Hofacker M, McFadden B, Conway S, Ordway C, Sanders D, Monaco R, Fragala MS, Arent SM, Stone JD, Kreutzer A, Oliver JM, Kisiolek J, Jagim AR, Hofacker M, Walker A, Pellegrino J, Rabideau M, McFadden B, Conway S, Sanders D, Ordway C, Monaco R, Fragala MS, Arent SM, Tok O, Pellegrino JK, Walker AJ, Sanders DJ, McFadden BA, Rabideau MM, Conway SP, Ordway CE, Bello M, Hofacker ML, Mackowski NS, Poyssick AJ, Capone E, Monaco RM, Fragala MS, Arent SM, Mumford PW, Holland AM, Kephart WC, Lowery RP, Mobley CB, Patel RK, Newton A, Beck DT, Roberts MD, Wilson JM, Young KC, Silver T, Ellerbroek A, Buehn R, Vargas L, Tamayo A, Peacock C, Antonio J, Ellerbroek A, Silver T, Buehn R, Vargas L, Tamayo A, Peacock C, Antonio J, Pollock A, Ellerbroek A, Silver T, Peacock C, Antonio J, Kreutzer A, Zavala P, Fleming S, Jones M, Oliver JM, Jagim A, Haun CT, Mumford PW, Hyde PN, Fairman CM, Kephart WC, Beck DT, Moon JR, Roberts MD, Kendall KL, Young KC, Hudson GM, Hannings T, Sprow K, DiPietro L, Kalman D, Ojalvo SP, Komorowski J, Zavala P, Fleming S, Jones M, Oliver J, Jagim A, Wallace B, Bergstrom H, Wallace K, Monsalves-Alvarez M, Oyharçabal S, Espinoza V, VanDusseldorp TA, Escobar KA, Johnson KE, Cole N, Moriarty T, Stratton M, Endito MR, Mermier CM, Kerksick CM, Romero MA, Mobley CB, Linden M, Meers GME, Rector RS, Roberts MD, Gills JL, Lu H, Parker K, Dobbins C, Guillory JN, Romer B, Szymanski D, Glenn J, Newmire DE, Rivas E, Deemer SE, Wildman R, Ben-Ezra V, Kerksick C, Gieske B, Stecker R, Smith C, Witherbee K, Lane MT, Byrd MT, Bell Z, Frith E, Lane LMC, Lane MT, Byrd MT, Bell Z, Frith E, Lane LMC, Peacock CA, Silver TA, Colas M, Mena M, Rodriguez W, Sanders GJ, Antonio J, Vansickle A, DiFiore B, Stepp S, Slack G, Smith B, Ruffner K, Mendel R, Lowery L, Hirsch KR, Mock MG, Blue MMN, Trexler ET, Roelofs EJ, Smith-Ryan AE, Conlin L, Aguilar D, Campbell BI, Norton L, Coles K, Trexler ET, Martinez N, Joy JM, Vogel RM, Hoover TH, Broughton KS, Dalton R, Sowinski R, Grubic T, Collins PB, Colletta A, Reyes A, Sanchez B, Kozehchain M, Jung YP, Rasmussen C, Murano P, Earnest CP, Greenwood M, Kreider RB, Grubic T, Dalton R, Sowinski R, Collins PB, Colletta A, Reyes A, Sanchez B, Kozehchain M, Jung YP, Rasmussen C, Murano P, Earnest CP, Greenwood M, Kreider RB, Sowinski R, Dalton R, Grubic T, Collins PB, Colletta A, Reyes A, Sanchez B, Kozehchain M, Jung YP, Rasmussen C, Murano P, Earnest CP, Greenwood M, Kreider RB, Durkalec-Michalski K, Jeszka J, Podgórski T, Kerksick C, Gieske B, Stecker R, Smith C, Witherbee K, Urbina S, Santos E, Villa K, Olivencia A, Bennett H, Lara M, Foster C, Wilborn C, Taylor L, Cholewa JM, Hewins A, Gallo S, Micensky A, de Angelis C, Carney C, Campbell B, Conlin L, Norton L, Rossi F, Koozehchian MS, Collins PB, Sowinski R, Grubic T, Dalton R, O’Connor A, Shin SY, Jung YP, Sanchez BK, Coletta A, Cho M, Reyes A, Rasmussen C, Earnest CP, Murano PS, Greenwood M, Kreider RB. Proceedings of the Thirteenth International Society of Sports Nutrition (ISSN) Conference and Expo. J Int Soc Sports Nutr 2016. [PMCID: PMC5025820 DOI: 10.1186/s12970-016-0144-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
P1 Impact of antioxidant-enriched nutrient bar supplementation on the serum antioxidant markers and physical fitness components of track and field athletes Lalitha Ramaswamy, Supriya Velraja P2 The effects of phosphatidic acid supplementation on fitness levels in resistance trained women Guillermo Escalante, Phil Harvey, Michelle Alencar, Bryan Haddock P3 The effects of phosphatidic acid supplementation on cardiovascular risk factors in resistance trained men Phil Harvey, Guillermo Escalante, Michelle Alencar, Bryan Haddock P4 The efficacy of sodium bicarbonate supplementation on physical capacity and selected biochemical markers in elite wrestlers Krzysztof Durkalec-Michalski, Jan Jeszka, Bogna Zawieja, Tomasz Podgórski P5 Effects of different nutritional strategies in hydration and physical performance in healthy well-trained males Ana Paula Trussardi Fayh, Alexandre Hideki Okano, Amanda Maria de Jesus Ferreira P6 Reduction of plasma creatine concentrations as an indicator of improved bioavailability Ralf Jäger, Martin Purpura, Roger C Harris P7 Effect of three different breakfast meals on energy intake and nutritional status in college-age women Molly M. Krause, Kiley A. Lavanger, Nina O. Allen, Allison E. Lieb, Katie A. Mullen, Joan M. Eckerson P8 Accuracy of the ASA24® Dietary Recall system for assessing actual dietary intake in normal weight college-age women. Kiley A. Lavanger, Molly M. Krause, Nina O. Allen, Allison E. Lieb, Katie A. Mullen, Joan M. Eckerson P9 β-aminoisobutyric acid does not regulate exercise induced UCP-3 expression in skeletal muscle Elisa Morales, Jeffrey Forsse, Thomas Andre, Sarah McKinley, Paul Hwang, Grant Tinsley, Mike Spillane, Peter Grandjean, Darryn Willoughby P10 The ability of collegiate football athletes to adhere to sport-specific nutritional recommendations A. Jagim, G. Wright, J. Kisiolek, M. Meinking, J. Ochsenwald, M. Andre, M.T. Jones, J. M. Oliver P11 A single session of low-volume high intensity interval exercise improves appetite regulation in overweight men Victor Araújo Ferreira, Daniel Costa de Souza, Victor Oliveira Albuquerque dos Santos, Rodrigo Alberto Vieira Browne, Eduardo Caldas Costa, Ana Paula Trussardi Fayh P12 Acute effects of oral peppermint oil ingestion on exercise performance in moderately-active college students Suresh T. Mathews, Haley D. Bishop, Clara R. Bowen, Yishan Liang, Emily A. West, Rebecca R. Rogers, Mallory R. Marshall, John K. Petrella P13 Associations in body fat and liver triglyceride content with serum health markers in sedentary and exercised rats fed a ketogenic diet, Western diet or standard chow over a 6-week period A. Maleah Holland, Wesley C. Kephart, Petey W. Mumford, C. Brooks Mobley, Ryan P. Lowery, Jacob M. Wilson, Michael D. Roberts P14 Physiological changes following competition in male and female physique athletes: A pilot study Eric T. Trexler, Katie R. Hirsch, Bill I. Campbell, Meredith G. Mock, Abbie E. Smith-Ryan P15 Relationship between cognition and hydration status in college students at a large Southwestern university Kate Zemek, Carol Johnston P16 Whey protein-derived exosomes increase protein synthesis in C2C12 myotubes C. Brooks Mobley, Petey W. Mumford, David D. Pascoe, Christopher M. Lockwood, Michael E. Miller, Michael D. Roberts P17 The effect of three different energy drinks on 1.5-mile running performance, oxygen consumption, and perceived exertion Gabriel J. Sanders, Willard Peveler, Brooke Warning, Corey A. Peacock P18 The Ketogenic diet improves rotarod performance in young and older rats Wesley C. Kephart, Petey W. Mumford, Ryan P. Lowery, Michael D. Roberts, Jacob M. Wilson P19 Absorption of bonded arginine silicate compared to individual arginine and silicon components David Sandler, Sara Perez Ojalvo, James Komorowski P20 Effects of a high (2.4 g/kg) vs. low/moderate (1.2 g/kg) protein intake on body composition in aspiring female physique athletes engaging in an 8-week resistance training program Bill I. Campbell, Danielle Aguilar, Andres Vargas, Laurin Conlin, Amey Sanders, Paola Fink-Irizarry, Layne Norton, Ross Perry, Ryley McCallum, Matthew R. Wynn, Jack Lenton P21 Effects of a high (2.4 g/kg) vs. low/moderate (1.2 g/kg) protein intake on maximal strength in aspiring female physique athletes engaging in an 8-week resistance training program Bill I. Campbell, Chris Gai, Seth Donelson, Shiva Best, Daniel Bove, Kaylee Couvillion, Jeff Dolan, Dante Xing, Kyshia Chernesky, Michael Pawela, Andres D. Toledo, Rachel Jimenez P22 Monitoring of female collegiate athletes over a competitive season reveals changes in nutritional biomarkers M. Rabideau, A. Walker, J. Pellegrino, M. Hofacker, B. McFadden, S. Conway, C. Ordway, D. Sanders, R. Monaco, M. S. Fragala, S. M. Arent P23 Comparison of prediction equations to indirect calorimetry in men and women athletes Jason D. Stone, Andreas Kreutzer, Jonathan M. Oliver, Jacob Kisiolek, Andrew R. Jagim P24 Regional variations in sweat-based electrolyte loss and changes in plasma electrolyte content in Division I female athletes over the course of a competitive season M. Hofacker, A. Walker, J. Pellegrino, M. Rabideau, B. McFadden, S. Conway, D. Sanders, C. Ordway, R. Monaco, M. S. Fragala, S. M. Arent P25 In-season changes in plasma amino acid levels in Division I NCAA female athletes Ozlem Tok, Joseph K. Pellegrino, Alan J. Walker, David J. Sanders, Bridget A. McFadden, Meaghan M. Rabideau, Sean P. Conway, Chris E. Ordway, Marissa Bello, Morgan L. Hofacker, Nick S. Mackowski, Anthony J. Poyssick, Eddie Capone, Robert M. Monaco, Maren S. Fragala, Shawn M. Arent P26 Effects of a ketogenic diet with exercise on serum markers of bone metabolism, IGF-1 and femoral bone mass in rats Petey W. Mumford, A. Maleah Holland, Wesley C. Kephart, Ryan P. Lowery, C. Brooks Mobley, Romil K. Patel, Annie Newton, Darren T. Beck, Michael D. Roberts, Jacob M. Wilson, Kaelin C. Young P27 Casein supplementation in trained men and women: morning versus evening Tobin Silver, Anya Ellerbroek, Richard Buehn, Leo Vargas, Armando Tamayo, Corey Peacock, Jose Antonio P28 A high protein diet has no harmful effects: a one-year crossover study in resistance-trained males Anya Ellerbroek, Tobin Silver, Richard Buehn, Leo Vargas, Armando Tamayo, Corey Peacock, Jose Antonio P29 SUP (Stand-up Paddling) athletes: nutritional intake and body composition Adam Pollock, Anya Ellerbroek, Tobin Silver, Corey Peacock, Jose Antonio P30 The effects of 8 weeks of colostrum and bio-active peptide supplementation on body composition in recreational male weight lifters A. Kreutzer, P. Zavala, S. Fleming, M. Jones, J. M. Oliver, A. Jagim P31 Effects of a Popular Women’s Thermogenic Supplement During an Energy-Restricted High Protein Diet on Changes in Body Composition and Clinical Safety Markers Cody T. Haun, Petey W. Mumford, Parker N. Hyde, Ciaran M. Fairman, Wesley C. Kephart, Darren T. Beck, Jordan R. Moon, Michael D. Roberts, Kristina L. Kendall, Kaelin C. Young P32 Three days of caffeine consumption following caffeine withdrawal yields small strength increase in knee flexors Geoffrey M Hudson, Tara Hannings, Kyle Sprow, Loretta DiPietro P33 Comparison of cellular nitric oxide production from various sports nutrition ingredients Doug Kalman, Sara Perez Ojalvo, James Komorowski P34 The effects of 8 weeks of bio-active peptide supplementation on training adaptations in recreational male weight lifters P. Zavala, S. Fleming, M. Jones, J. Oliver, A. Jagim P35 Effects of MusclePharm Assault BlackTM on lower extremity spinal excitability and postactivation potentiation: A pilot study Brian Wallace, Haley Bergstrom, Kelly Wallace P36 Effects of four weeks of Ketogenic Diet alone and combined with High intensity Interval Training or Continuous-Moderate intensity on body composition, lipid profile and physical performance on healthy males Matias Monsalves-Alvarez, Sebastian Oyharçabal, Victoria Espinoza P37 Effect of branched-chain amino acid supplementation on creatine kinase, muscular performance, and perceived muscle soreness following acute eccentric exercise Trisha A. VanDusseldorp, Kurt A. Escobar, Kelly E. Johnson, Nathan Cole, Terence Moriarty, Matthew Stratton, Marvin R. Endito, Christine M. Mermier, Chad M. Kerksick P38 Effects of endurance training on markers of ribosome biogenesis in rodents fed a high fat diet Matthew A. Romero, C. Brooks Mobley, Melissa Linden, Grace Margaret-Eleanor Meers, R. Scott Rector, Michael D. Roberts P39 The effects of acute citrulline-malate on lower-body isokinetic performance in recreationally active individuals Joshua L Gills, Hocheng Lu, Kimberly Parker, Chris Dobbins, Joshua N Guillory, Braden Romer, David Szymanski, Jordan Glenn P40 The effect pre-ingested L-isoleucine and L-leucine on blood glucose responses and glycemic hormones in healthy inactive adults: Preliminary data. Daniel E. Newmire, Eric Rivas, Sarah E. Deemer, Robert Wildman, Victor Ben-Ezra P41 Does protein and source impact substrate oxidation and energy expenditure during and after moderate intensity treadmill exercise? C Kerksick, B Gieske, R Stecker, C Smith, K Witherbee P42 Effects of a pre-workout supplement on peak power and power maintenance during lower and upper body testing Michael T. Lane, M. Travis Byrd, Zachary Bell, Emily Frith, Lauren M.C. Lane P43 Effects of a pre-workout supplement on peak power production during lower and upper body testing in college-age females Michael T. Lane, M. Travis Byrd, Zachary Bell, Emily Frith, Lauren M.C. Lane P44 A comparison of whey versus casein protein supplementation on resting metabolic rate and body composition: a pilot study Corey A. Peacock, Tobin A. Silver, Megan Colas, Mauricio Mena, Winter Rodriguez, Gabriel J. Sanders, Jose Antonio P45 A novel mixed-tocotrienol intervention enhances recovery after eccentric exercise: preliminary findings Andrea Vansickle, Brittany DiFiore, Stephanie Stepp, Grant Slack, Bridget Smith, Kayla Ruffner, Ronald Mendel, Lonnie Lowery P46 The effects of post-exercise ingestion of a high molecular weight glucose on cycle performance in female cyclists Katie R. Hirsch, Meredith G. Mock, Malia M.N. Blue, Eric T. Trexler, Erica J. Roelofs, Abbie E. Smith-Ryan P47 Inclusive vs. exclusive dieting and the effects on body composition in resistance trained individuals Laurin Conlin, Danielle Aguilar, Bill I. Campbell, Layne Norton, Katie Coles, Eric T. Trexler, Nic Martinez P48 A whey protein hydrolysate may positively augment resting metabolism compared to intact whey protein Jordan M. Joy, Roxanne M. Vogel, Thomas H. Hoover, K. Shane Broughton P49 Seven days of high and low dose creatine nitrate supplementation I: hepatorenal, glucose and muscle enzyme function R Dalton, R Sowinski, T Grubic, PB Collins, A Colletta, A Reyes, B Sanchez, M Kozehchain, YP Jung, C Rasmussen, P Murano, CP Earnest, M Greenwood, RB Kreider P50 Seven days of high and low dose creatine nitrate supplementation II: performance T Grubic, R Dalton, R Sowinski, PB Collins, A Colletta, A Reyes, B Sanchez, M Kozehchain, YP Jung, C Rasmussen, P Murano, CP Earnest, M Greenwood, RB Kreider P51 Seven days of high and low dose creatine nitrate supplementation III: hemodynamics R Sowinski, R Dalton, T Grubic, PB Collins, A Colletta, A Reyes, B Sanchez, M Kozehchain, YP Jung, C Rasmussen, P Murano, CP Earnest, M Greenwood, RB Kreider P52 The efficacy of a β-hydroxy-β-methylbutyrate supplementation on physical capacity, body composition and biochemical markers in highly-trained combat sports athletes Krzysztof Durkalec-Michalski, Jan Jeszka, Tomasz Podgórski P53 Does protein and source impact substrate oxidation and energy expenditure during and after moderate intensity treadmill exercise? C Kerksick, B Gieske, R Stecker, C Smith, K Witherbee P54 Effects of 30 days of Cleanse™ supplementation on measure of body composition, waist circumference, and markers of gastrointestinal distress in females Stacie Urbina, Emily Santos, Katelyn Villa, Alyssa Olivencia, Haley Bennett, Marissa Lara, Cliffa Foster, Colin Wilborn, Lem Taylor P55 The effects of moderate- versus high-load training on body composition, muscle growth, and performance in college aged females Jason M Cholewa, Amy Hewins, Samantha Gallo, Ashley Micensky, Christian De Angelis, Christopher Carney, Bill Campbell, Laurin Conlin, Layne Norton, Fabricio Rossi P56 Effect of a multi-ingredient preworkout supplement on cognitive function and perceptions of readiness to perform MS Koozehchian, PB Collins, R Sowinski, T Grubic, R Dalton, A O’Connor, SY Shin, Y Peter Jung, BK Sanchez, A Coletta, M Cho, A Reyes, C Rasmussen, CP Earnest, PS Murano, M Greenwood, RB Kreider
Collapse
|
38
|
Denton EJ, Hart D, Wainer Z, Wright G, Russell PA, Conron M. Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre. Intern Med J 2016; 46:946-54. [DOI: 10.1111/imj.13132] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 04/19/2016] [Accepted: 05/06/2016] [Indexed: 11/30/2022]
Affiliation(s)
- E. J. Denton
- Department of Respiratory and Sleep Medicine; St Vincent's Hospital Melbourne; Melbourne Victoria Australia
| | - D. Hart
- Department of Respiratory and Sleep Medicine; St Vincent's Hospital Melbourne; Melbourne Victoria Australia
| | - Z. Wainer
- Peter MacCallum Cancer Centre; Melbourne Victoria Australia
| | - G. Wright
- Department of Surgery; The University of Melbourne, St Vincent's Hospital Melbourne; Melbourne Victoria Australia
| | - P. A. Russell
- Department of Anatomical Pathology; The University of Melbourne, St Vincent's Hospital Melbourne; Melbourne Victoria Australia
| | - M. Conron
- Department of Respiratory and Sleep Medicine; St Vincent's Hospital Melbourne; Melbourne Victoria Australia
| |
Collapse
|
39
|
Stein A, Wright G, Yager KG, Doerk GS, Black CT. Selective directed self-assembly of coexisting morphologies using block copolymer blends. Nat Commun 2016; 7:12366. [PMID: 27480327 PMCID: PMC4974660 DOI: 10.1038/ncomms12366] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 06/24/2016] [Indexed: 11/25/2022] Open
Abstract
Directed self-assembly (DSA) of block copolymers is an emergent technique for nano-lithography, but is limited in the range of structures possible in a single fabrication step. Here we expand on traditional DSA chemical patterning. A blend of lamellar- and cylinder-forming block copolymers assembles on specially designed surface chemical line gratings, leading to the simultaneous formation of coexisting ordered morphologies in separate areas of the substrate. The competing energetics of polymer chain distortions and chemical mismatch with the substrate grating bias the system towards either line/space or dot array patterns, depending on the pitch and linewidth of the prepattern. This is in contrast to the typical DSA, wherein assembly of a single-component block copolymer on chemical templates generates patterns of either lines/spaces (lamellar) or hexagonal dot arrays (cylinders). In our approach, the chemical template encodes desired local spatial arrangements of coexisting design motifs, self-assembled from a single, sophisticated resist. There is a limited range of structures available in nanolithography using directed self-assembled block copolymers. Here, Black and co-workers expand directed self-assembly chemical patterning by using a blend of lamellar and cylinder forming block copolymers on surface chemical line gratings.
Collapse
Affiliation(s)
- A Stein
- Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Wright
- Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K G Yager
- Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G S Doerk
- Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C T Black
- Center for Functional Nanomaterials, Brookhaven National Laboratory, Upton, New York 11973, USA
| |
Collapse
|
40
|
Abstract
The mean, pulsatile and total power outputs of the Centrimed centrifugal pump, the Stöckert roller pump, the Polystan flat-plate compression pump and the Keele ventricle pump were compared when loaded with an artificial circulation system. The hydraulic power in the model 'aorta' was affected by the pump output, the peripheral resistance and the model compliance, but not the pulse repetition frequency. Under similar operating conditions, the power generated by the pumps differed markedly and these differences were almost entirely due to the pulsatile content of the pressure and flow waveforms. Compared to the human heart, the Stöckert pump generated only about 12.4% as much pulsatile power, while the Polystan pump generated 82.0% and the Keele pump generated 271.9% at 4.01 min-1 and 80 strokes min-1. It is suggested that the benefits of pulsatile blood flow may be derived from the lateral transmission of energy and the promotion of tissue fluid movement. The failure of some investigators to detect these benefits may be because the pulsatile content of the pump output was insufficient.
Collapse
Affiliation(s)
- G. Wright
- University of Keele and North Staffordshire Hospital Centre
| |
Collapse
|
41
|
Khan KN, Chana R, Ali N, Wright G, Webster AR, Moore AT, Michaelides M. Advanced diagnostic genetic testing in inherited retinal disease: experience from a single tertiary referral centre in the UK National Health Service. Clin Genet 2016; 91:38-45. [PMID: 27160483 DOI: 10.1111/cge.12798] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 04/15/2016] [Accepted: 05/05/2016] [Indexed: 11/29/2022]
Abstract
In 2013, as part of our genetic investigation of patients with inherited retinal disease, we utilized multigene panel testing of 105 genes known to cause retinal disease in our patient cohorts. This test was performed in a UK National Health Service (NHS) accredited laboratory. The results of all multigene panel tests requested between 1.4.13 and 31.8.14 were retrospectively reviewed. All patients had been previously seen at Moorfields Eye Hospital, London, UK and diagnosed with an inherited retinal dystrophy after clinical examination and detailed retinal imaging. The results were categorized into three groups: (i) Testing helped establish a certain molecular diagnosis in 45 out of 115 (39%). Variants in USH2A (n = 6) and RP1 (n = 4) were most common. (ii) Definitive conclusions could not be drawn from molecular testing alone in 13 out of 115 (11%) as either insufficient pathogenic variants were discovered or those identified were not consistent with the phenotype. (iii) Testing did not identify any pathogenic variants responsible for the phenotype in 57 out of 115 (50%). Multigene panel testing performed in an NHS setting has enabled a molecular diagnosis to be confidently made in 40% of cases. Novel variants accounted for 38% of all identified variants. Detailed retinal phenotyping helped the interpretation of specific variants. Additional care needs to be taken when assessing polymorphisms in genes that have been infrequently associated with disease, as historical techniques were not as rigorous as contemporary ones. Future iterations of sequencing are likely to offer higher sensitivity, testing a broader range of genes, more rapidly and at a reduced cost.
Collapse
Affiliation(s)
- K N Khan
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK.,St. James's University Hospital, Leeds, UK
| | - R Chana
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK
| | - N Ali
- Moorfields Eye Hospital, London, UK
| | - G Wright
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK
| | - A R Webster
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK
| | - A T Moore
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK
| | - M Michaelides
- Moorfields Eye Hospital, London, UK.,UCL Institute of Ophthalmology, London, UK
| |
Collapse
|
42
|
Abstract
Over half of all Australians are classified as overweight or obese and this is increasing by 1% of the population per year. Obesity is linked with a range of health ailments including type 2 diabetes, heart diseases and some cancers. At a population level it is well accepted that obesity is a result of the increasing use of modern technology, resulting in decreased energy expenditure, in combination with easily available high energy density foods, the “obesogenic environment”. In the modern environment, there are two major areas of management to assist the overweight and obese. Both include a change in lifestyle. Future strategies in weight management should include reduction in energy density and increase in daily physical activity.
Collapse
Affiliation(s)
- S Pal
- Department of Nutrition, Dietetics and Food Sciences, Curtin University of Technology, Perth, Western Australia
| | - G Egger
- School of Health Sciences, Deakin University, Melbourne, Australia
| | - G Wright
- Lifechoice Clinic, Perth Australia
| |
Collapse
|
43
|
Mcdonald S, Wright G. AB1048 The Transformation of Inpatient Rheumatology Services in A Post-Biologics Era. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Yardley DA, Chandra P, Hart L, Wright GS, Ward P, Mani A, Shastry M, Finney L, Guo S, DeBusk LM, Hainsworth JD, Burris III HA. Abstract P1-14-06: A phase II randomized study with eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer- Final analysis of primary endpoint and correlative analysis results. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eribulin mesylate (Er) is a non-taxane inhibitor of microtubule growth that results in G2-M cell cycle arrest, disruption of normal mitotic spindles and apoptosis. Er demonstrated an overall survival (OS) but not progression free survival (PFS) advantage in anthracycline and taxane refractory breast cancer pts. This OS rather than PFS benefit has been attributed to Er's potential to suppress new metastases through its effects on the epithelial mesenchymal transition (EMT) pathway, even in the absence of an effect on the primary tumor or established metastases. In this study ErC was compared to TC, a standard regimen for (neo) adjuvant treatment. A companion exploratory analysis examined the EMT markers E-cadherin and vimentin, as well as the endothelial marker CD-31 assessing tumor vasculature. Final assessments of the primary endpoint of pathological complete response (pCR) and results of the correlative studies will be presented.
Methods: Women with histologically confirmed invasive HER2-negative (IHC 0-1+ or FISH/SISH negative), cT1-3, cN0-2, M0 (pN3a disease allowed) adenocarcinoma of the breast were eligible. Following a 10 pt lead-in to confirm the safety/feasibility of ErC, pts were randomized 2:1. Arm 1, Er 1.4 mg/m2 IV (Days 1 & 8) and C 600 mg/m2 IV (Day 1); Arm 2, T 75 mg/m2 IV and C 600 mg/m2 IV on Day 1, both regimens administered q 21 days x 6 cycles followed by surgery. Tumor samples were collected at baseline and from residual breast cancer at the time of surgery. Samples were assayed for E-cadherin, vimentin, and CD-31 expression by immunohistochemistry.
Results: Enrollment was completed 4/2014 (76 pts); 10 pts in lead-in phase, 66 pts were randomized (Arm 1, 44; Arm 2, 22). In the randomized population, 77% had invasive ductal adenocarcinoma; median tumor size 3.1 cm (range, 0.4-10cm; 29.5% were T3); axillary nodes clinically positive in 52%. 34% of pts were triple negative (TN). 59 pts (89%) underwent surgery after receiving neoadjuvant chemotherapy (NAC) on study. pCR rates were 9% and 18% on the TC and ErC arms respectively. 4/7 pts with pCR on the ErC arm were TN. tumor samples were analyzed from 69 pts (including lead-in pts) for expression of the EMT biomarkers. Of these, 40 pts had paired pre- and post-treatment samples, and 29 pts had either a pre- or post-treatment sample (including 8 pre-treatment samples from pts who achieved pCR). In pre-treatment tumor specimens (61 samples), E-cadherin levels were modest-high in 80%, vimentin expression was seen in 39%, and CD-31 expression observed in 21% of the samples. Analysis of pre- and post-treatment paired specimens and differential effects according to treatment regimen will be presented.
Conclusion: The observed pCR rate of 18% with ErC in this HER2- pt population was comparable with other NAC regimens. Correlative evaluation of EMT markers and tumor vascular density with response is ongoing and will be presented.
Citation Format: Yardley DA, Chandra P, Hart L, Wright GS, Ward P, Mani A, Shastry M, Finney L, Guo S, DeBusk LM, Hainsworth JD, Burris III HA. A phase II randomized study with eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer- Final analysis of primary endpoint and correlative analysis results. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-06.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - P Chandra
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - L Hart
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - GS Wright
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - P Ward
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - A Mani
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - M Shastry
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - L Finney
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - S Guo
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - LM DeBusk
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - JD Hainsworth
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - HA Burris III
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Brentwood, TN; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, FL; Sarah Cannon Research Institute/Florida Cancer Specialists, New Port Richey, FL; Sarah Cannon Research Institute/Oncology Hematology Care, Inc, Cincinnati, OH; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
45
|
Melisko M, Yardley DA, Blackwell K, Forero A, Ma C, Montero A, Daniel BR, Wright G, Fehrenbacher L, Chew H, Ferrario C, Nanda R, Seiler M, Guthrie T, Vance K, Ouellette G, He Y, Bagley RG, Zhang J, Vahdat LT. Abstract OT1-03-15: The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot1-03-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Glycoprotein NMB (gpNMB) is an internalizable transmembrane protein overexpressed in approximately 20% of breast cancer (BC), including approximately 40% of TNBC. gpNMB is a poor prognostic marker in BC (Rose CCR 2010) and preclinically has been implicated in tumor invasion, metastasis, and angiogenesis. GV is a novel antibody-drug conjugate targeting the potent cytotoxin monomethylauristatin E (MMAE) to gpNMB overexpressing cancer cells.
In a Phase I/II study and the Phase II "EMERGE" study, GV demonstrated promising activity with TNBC patients (pts) deriving the greatest benefit and exhibiting the highest degree of gpNMB overexpression. GV was well-tolerated with the most frequent treatment-related toxicities consisting of rash, neutropenia, and neuropathy. In subset analyses of the EMERGE trial, objective response rate (ORR) was 30% (7/23) for GV vs. 9% (1/11) for investigator's choice in tumors with gpNMB overexpression (>25% of tumor epithelium); 18% (5/28) vs. 0% (0/11) in TNBC; and 40% (4/10) vs. 0% (0/6) in gpNMB-overexpressing TNBC for GV and IC respectively, with apparent improvements in progression-free survival (PFS; hazard ratio (HR) = 0.11) and overall survival (OS; HR = 0.14).
Trial design
The METRIC Trial (NCT#01997333) is an international (USA, CA, Aus), two-arm phase II study. Pts are randomized 2:1 to GV (1.88 mg/kg IV q 21 days) or capecitabine, a current standard of care for this population (2,500 mg/m2 daily for d1-14, q21 days) until progression or intolerance. Crossover is not permitted.
Eligibility criteria
Key eligibility criteria include: >25% of tumor epithelium gpNMB+ by central immunohistochemistry (IHC) screening of archival tissue; estrogen receptor and progesterone receptor <10% and HER2 negative [0-1+ IHC, or ISH copy number <4.0/ratio <2.0] by local assessment; ECOG 0-1; taxane resistance; anthracycline exposure (if indicated); <2 chemotherapy regimens for advanced BC; measurable disease; no persistent Grade >2 toxicity.
Specific aims
The primary endpoint is PFS per independent, blinded central review committee according to RECIST 1.1. Secondary endpoints are ORR, duration of response, OS, safety, pharmacokinetics and pharmacodynamics. Exploratory endpoints are quality of life and/or cancer-related pain.
Statistical methods and target accrual
The trial has 85% power to detect a PFS HR of 0.64 with two sided α = 0.05. The hypothesized median PFS is 4.0 months for capecitabine and 6.25 months for GV. Target accrual is open for 300 pts.
Citation Format: Melisko M, Yardley DA, Blackwell K, Forero A, Ma C, Montero A, Daniel BR, Wright G, Fehrenbacher L, Chew H, Ferrario C, Nanda R, Seiler Jr M, Guthrie T, Vance K, Ouellette G, He Y, Bagley RG, Zhang J, Vahdat LT. The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-03-15.
Collapse
Affiliation(s)
- M Melisko
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - DA Yardley
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - K Blackwell
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - A Forero
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - C Ma
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - A Montero
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - BR Daniel
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - G Wright
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - L Fehrenbacher
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - H Chew
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - C Ferrario
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - R Nanda
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - M Seiler
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - T Guthrie
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - K Vance
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - G Ouellette
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - Y He
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - RG Bagley
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - J Zhang
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| | - LT Vahdat
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC; Duke University Medical Center; University of Alabama; Washington University; Cleveland Clinic; Chattanooga Oncology Hematology Associates; Florida Cancer Specialists; Kaiser Permanente; University of California Davis Comprehensive Cancer Center; Segal Cancer Center-Jewish General Hospital; University of Chicago; Crescent City Research Consortium, LLC; Baptist Cancer Institute; Alabama Oncology; Celldex Therapeutics, Inc.; Weill Cornell Medical College
| |
Collapse
|
46
|
Hernandez L, Kim MK, Noonan AM, Sagher E, Kohlhammer H, Wright G, Lyle LT, Steeg PS, Anver M, Bowtell DD, Annunziata CM. A dual role for Caspase8 and NF- κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival. Cell Death Discov 2015; 1:15053. [PMID: 28179987 PMCID: PMC5198842 DOI: 10.1038/cddiscovery.2015.53] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 09/24/2015] [Accepted: 09/26/2015] [Indexed: 12/15/2022] Open
Abstract
Ovarian cancer is a deadly disease characterized by primary and acquired resistance to chemotherapy. We previously associated NF-κB signaling with poor survival in ovarian cancer, and functionally demonstrated this pathway as mediating proliferation, invasion and metastasis. We aimed to identify cooperating pathways in NF-κB-dependent ovarian cancer cells, using genome-wide RNA interference as a loss-of-function screen for key regulators of cell survival with IKKβ inhibition. Functional genomic screen for interactions with NF-κB in ovarian cancer showed that cells depleted of Caspase8 died better with IKKβ inhibition. Overall, low Caspase8 was associated with shorter overall survival in three independent gene expression data sets of ovarian cancers. Conversely, Caspase8 expression was markedly highest in ovarian cancer subtypes characterized by strong T-cell infiltration and better overall prognosis, suggesting that Caspase8 expression increased chemotherapy-induced cell death. We investigated the effects of Caspase8 depletion on apoptosis and necroptosis of TNFα-stimulated ovarian cancer cell lines. Inhibition of NF-κB in ovarian cancer cells switched the effects of TNFα signaling from proliferation to death. Although Caspase8-high cancer cells died by apoptosis, Caspase8 depletion downregulated NF-κB signaling, stabilized RIPK1 and promoted necroptotic cell death. Blockage of NF-κB signaling and depletion of cIAP with SMAC-mimetic further rendered these cells susceptible to killing by necroptosis. These findings have implications for anticancer strategies to improve outcome for women with low Caspase8-expressing ovarian cancer.
Collapse
Affiliation(s)
- L Hernandez
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - M K Kim
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - A M Noonan
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - E Sagher
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - H Kohlhammer
- Metabolism Branch, Center for Cancer Research, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - G Wright
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National
Cancer Institute, Bethesda, MD
20892-1906, USA
| | - L T Lyle
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - P S Steeg
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| | - M Anver
- Pathology/Histotechnology Laboratory, LASP, Leidos Biomedical Research, Inc.,
Frederick, MD
21702-1201, USA
| | - D D Bowtell
- Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer
Centre, East Melbourne, Victoria, Australia
- The Department of Pathology, University of Melbourne, Parkville,
Victoria, Australia
| | - on behalf of the Australian Ovarian Cancer Study Group
57
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
- Metabolism Branch, Center for Cancer Research, National Cancer Institute,
Bethesda, MD
20892-1906, USA
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National
Cancer Institute, Bethesda, MD
20892-1906, USA
- Pathology/Histotechnology Laboratory, LASP, Leidos Biomedical Research, Inc.,
Frederick, MD
21702-1201, USA
- Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer
Centre, East Melbourne, Victoria, Australia
- The Department of Pathology, University of Melbourne, Parkville,
Victoria, Australia
| | - C M Annunziata
- Women’s Malignancies Branch, National Cancer Institute,
Bethesda, MD
20892-1906, USA
| |
Collapse
|
47
|
Malone S, Wright G, Lacelle M, Buckley L, Studinski R, Haridass A, Malone C, Musclow B, Morgan S. Evaluation of a Penile Clamp to Improve Bladder Filling in Patients Undergoing Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Jagim AR, Wright G, Schultz K, St Antoine C, Jones MT, Oliver JM. Effects of acute ingestion of a multi-ingredient pre-workout supplement on lower body power and anaerobic sprint performance. J Int Soc Sports Nutr 2015. [PMCID: PMC4595097 DOI: 10.1186/1550-2783-12-s1-p49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
El Sayed G, Tarff S, O'Beirne J, Wright G. Endoscopy management algorithms: role of cyanoacrylate glue injection and self-expanding metal stents in acute variceal haemorrhage. Frontline Gastroenterol 2015; 6:208-216. [PMID: 26167267 PMCID: PMC4484373 DOI: 10.1136/flgastro-2013-100428] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 05/24/2014] [Accepted: 05/26/2014] [Indexed: 02/04/2023] Open
Abstract
Mortality from acute variceal bleeding (AVB) has improved markedly over the last 2-3 decades due to increased specialisation and standardisation of medical and endoscopic practice culminating in the production of consensus guidance based on expert opinion. Nonetheless, despite greater exposure, training and endoscopic practices, 30-day mortality still remains high at around 30%. This is a reflection of the high morbidity with liver disease, and limited endoscopic experience and/or endoscopic techniques used by the majority of general endoscopists. Clinical necessity defines our drive for further endoscopic innovation to improve 'best practice' and, therefore, clinical outcomes accordingly. Sclerotherpy, variceal band ligation and/or rescue balloon tamponade have been entrenched in most treatment algorithms over the decades. However, in recent years and albeit limited to specialised liver centres, cyanoacrylate glue injection therapy (for oesophageal and gastric varices), and the placement of a self-expanding metallic stent for oesophageal varices have begun to offer improved endoscopic care in experienced hands. Yet even in specialised centres, their application is sporadic and operator dependent. Here, we discuss the evidence of these newer endoscopic approaches, and hope to propose their inclusion in endoscopic therapy algorithms for 'best practice' management of AVB in all appropriately supported endoscopy units.
Collapse
Affiliation(s)
- G El Sayed
- Department of Gastroenterology, Basildon & Thurock University Hospital, London, UK
| | - S Tarff
- Department of Gastroenterology, Basildon & Thurock University Hospital, London, UK
| | - J O'Beirne
- Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK
| | - G Wright
- Department of Gastroenterology, Basildon & Thurock University Hospital, London, UK
- Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK
| |
Collapse
|
50
|
Okano T, Filippucci E, Draghessi A, Di Carlo M, Carotti M, Salaffi F, Wright G, Grassi W. SAT0593 Ultrasonographic Evaluation of Joint Damage in Knee Osteoarthritis: A Comparison with Conventional Radiography. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|